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ABSTRACT 
Platelets play a critical role in haemostasis and through platelet adhesion and aggregation 
ensure the integrity of the cardiovascular system is maintained in the event of an injury. The 
actin cytoskeleton plays a pivotal role in mediating the massive shape change involved in 
platelet spreading, aggregation and clot retraction at sites of injury. The formation of actin 
structures, such as filopodia, lamellipodia and stress fibres, are well characterised in platelets 
but little is known about the role of a recently characterised actin structure, referred to as the 
actin nodule. Investigating the actin nodules relied on fixed cell studies but live cell studies 
would greatly enhance our understanding of the role of actin nodules in platelets. However, 
introduction of fluorescent actin labels to human platelets for live cell imaging studies is 
currently not possible. Therefore, the aims of this thesis are to characterise the actin nodule 
and elucidate their role in platelet spreading. To achieve this, platelets from the Lifeact-GFP 
transgenic mouse were used. For human platelets, the intracellular delivery of the actin label, 
Lifeact, into human platelets using pH (low) insertion peptide was investigated. Additionally, 
the use of fluorescent labels and luminescent europium coated gold nanoparticles is explored 
as potential labels for multimodal imaging of human platelet actin nodule dynamics. 
 
Through live cell imaging studies of Lifeact-GFP mouse platelets, I have characterised actin 
nodules in mouse platelets as a transient, surface-proximal, stationary actin structure which 
requires actin polymerisation downstream of SFK activity and the presence of Arp 2/3 
complex. Additionally, their co-localisation with αIIb staining and, from previous work in our 
lab, with vinculin, talin and paxillin suggest a role for the actin nodule in platelet adhesion. 
 
I have also demonstrated that pHLIP is able to deliver Lifeact and luminescent europium 
coated gold nanoparticles into the cytoplasm of human platelets. Once delivered, Lifeact was 
able to label the actin cytoskeleton and consequently this represents a step forward in the 
ability to image actin dynamics in human platelets. Finally, I have shown that gold 
nanoparticles can be functionalised with multiple moieties and that they are suitable as labels 
for multiple imaging modalities. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 INTRODUCTION 
Delivery of substances, drugs, proteins, DNA, imaging probes to name but a few, into cells is 
of great interest to many areas of the life sciences. Whether the interest is in the area of 
treating illnesses, such as cancer, by effective and targeted delivery of drugs or in elucidating 
the many functions of a given cell type via biochemical assays and various imaging 
modalities, they all share a similar end in requiring a suitable method of delivery to perform 
the desired task. There are many different types of delivery systems available or under 
investigation, from the complex polymer spheres enabling cell targeting or time-dependent 
release in whole organisms to the simple method of membrane permeablisation of ex vivo or 
in vitro cell cultures. This work is concerned with delivery of imaging agents into cells, in 
particular platelets, to enable imaging of platelet dynamics with high spatial and temporal 
resolution. 
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1.2 PLATELETS 
1.2.1 Platelet Overview 
Platelets are small (0.5 – 3 μm), anucleate cells that circulate in the peripheral blood and play 
a critical role in haemostasis. Their small size means they are marginalised to the the edge of 
the vessel by the red blood cells. Their position next to the endothelium enables them to 
quickly respond to damage, arresting any or further blood loss. As well as their role in 
thrombosis formation, platelets are also implicated in other processes including, 
inflammation, bacteria removal and metastasis of cancer through their interaction with 
neutrophils (Weksler, 1983, Bazzoni et al., 1991, Tang et al., 2002, Wong et al., 2013, Jurasz 
et al., 2004, Takagi et al., 2013). 
 
Platelets are produced in the bone marrow by their multi-nucleated precursor cells, 
megakaryocytes, which are descended from haematopoietic stem cells (Hartwig and Italiano, 
2003). The cells produce long protrusions referred to as pro-platelets from which platelets 
bud. The process of platelet release from pro-platelets is not fully understood but it is believed 
that pro-platelet formation occurs in the osteobalstic niche. The pro-platelets protrude through 
the endothelial cells, enabling release of platelets directly into the vasculature. Each cell 
generates 2000 - 3000 platelets. 
 
Due to their anucleate state, these cells have a short lifespan, 7 – 10 days, in the circulating 
blood and have very limited protein synthesis (Watson and Harrison, 2007). Platelets contain 
many signalling proteins and surface receptors which result in high sensitivity of platelets to 
external stimulus. This enables fast activation and subsequent rapid aggregation and clot 
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formation, following vessel wall damage (Figure 1.2.1). Consequently, arresting blood loss 
through the damaged vessel. 
 
 
(Vallenius, 2004) 
 
1.2.2 Platelet structure 
The megakaryocyte produces all the platelet-specific proteins, organelles and membrane 
systems found in platelets. The platelet contains many of the same organelles as most cells, 
including lysosymes, mitochondria and actin filaments and tubules of the cytoskeleton but 
they do not contain a nucleus (Figure 1.2.2). They also contain dense granules, α-granules and 
an open canalicular system. 
Chapter 1 – General Introduction 
Page | 4 
 
 
 
Each human platelet contains; a few lysosomes, 50 to 80 α-granules, which contain more than 
300 secretable proteins, including adhesion molecules, such as P-selectin, chemokines, 
cytokines, fibrinolytic regulators, immunologic modulators and a variety of coagulation, 
compliment, growth, proangiogenic and antiangiogenic factors and three to eight dense (δ-) 
granules, these contain mostly small molecules, including calcium, magnesium, 
polyphosphate, ATP, ADP, GTP, GDP, and serotonin (Kahr, 2009). 
 
Platelets have an open canalicular system (OCS) which is a reservoir of membrane that is 
evaginated when the platelet spreads, as such, contributing to the increase in surface area to 
volume ratio of the platelets (White and Clawson, 1980). This membrane is a series of 
interconnected tubes that are in contact with the external environment. 
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1.2.3 Platelet activation and thrombus formation 
The platelet membrane contains many receptor proteins to multiple agonists (Figure 1.2.3). 
These surface receptor proteins transmit signals from the extracellular environment to the cell 
interior. In platelets there are two categories of surface receptors; G protein-coupled receptors, 
GPCRs, and tyrosine kinase-linked receptors: 
 
GPCR receptors. The seven transmembrane proteins in the GPCR class induce platelet 
activation through a G protein. Included in this class of proteins are; P2Y12, protease activated 
receptor 1, PAR1, thromboxane A2 receptor, TxA2R, and prostacyclin receptor, PGI2R which 
bind ADP, thrombin, TxA2 and PGI2, respectively. 
 
Tyrosine kinase-linked receptors. The platelet receptors in the tyrosine kinase-linked receptors 
category signal through activation of tyrosine kinases such as Src and Syk. Included in this 
class of proteins are; GPVI and GPIb-IX-V which bind collagen and von Willebrand factor, 
VWF, respectively, and integrins, including αIIbβ3 and α2β1. αIIbβ3 is the most prolific 
membrane protein on the platelet and mediates binding of fibrinogen and VWF and α2β1 is 
the main platelet collagen receptor (Phillips et al., 2001, Clemetson and Clemetson, 2001).  
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While circulating in the blood, the platelets are kept in their resting state by the production 
and release of nitric oxide, NO, heparin and prostacyclin, PGI2, by the endothelial cells of the 
blood vessels. These inhibitors prevent activation and binding of platelets to the healthy 
endothelium. Damage to the endothelium exposes the basement membrane which contains 
matrix proteins including, collagen and laminin. Collagen is considered to be the most 
thrombogenic constistuent of vessel wall. Activation of platelets leads to occlusion of the 
exposed subendothelial matrix, consequently preventing further blood loss. Platelet activation 
occurs via a defined sequence of events (Figure 1.2.4) (Varga-Szabo et al., 2008, Rivera et al., 
2009). 
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1. Tethering: the receptors and mechanisms of platelet tethering and adhesion are dependent 
upon the rheological conditions in the vessel. In the venous system, for instance, where 
shear rate is low, the platelet integrin α2β1 binds to the collagen, tethering the platelet to 
the exposed surface. However, this interaction has a slow on/off rate, so does not occur in 
vessels with high shear rates. Instead, the platelet tethering occurs through binding of 
VWF which has been immobilised on the exposed collagen, to the platelets GPIb-IX-V 
complex (Berndt et al., 2001). This interaction has a fast on/off rate resulting in transient 
association between VWF and GPIb-IX-V and causes platelets to roll along the exposed 
matrix until stable adhesion occurs. 
2. Integrin activation and stable adhesion: The interaction of VWF with GPIb-IX-V 
enables binding of the low affinity collagen receptor GPVI to collagen. This interaction 
activates the platelet integrins α2β1 and αIIbβ3 which bind collagen and VWF, 
respectively. This inside-out activation of the integrins leads to stable adhesion of the 
platelet to the exposed surface as a consequence of the high affinity and slow dissociation 
rates of the integrins for their ligands. 
3. Spreading: Following stable adhesion, massive reorganisation of the actin cytoskeleton 
leads to a characteristic set of morphological changes of the platelet. This includes the 
formation of filopodia and lamellipodia in a process referred to as platelet spreading. 
Platelet spreading causes an increase in the platelet surface area, further strengthening the 
platelet adhesion. 
4. Procoagulant activity: Platelet activation causes exposure of the membrane phospholipid 
phosphatidylserine, PS, which provides a procoagulant surface to support thrombin 
formation. The presence of thrombin results in activation of additional platelets via 
binding to protease activated receptor 1, PAR1. 
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5. Clot retraction: Thrombin also cleaves fibrinogen, thus enabling generation of a fibrin 
mesh. The fibrin mesh helps to further block the gap in the endothelium and further 
strengthens the thrombus through clot retraction. Clot retraction is mediated by the 
interaction of fibrin with the actin cytoskeleton via their binding to αIIbβ3. 
 
 
1.2.4 Platelet shape change 
Platelet activation involves a characteristic set of morphological changes (Figure 1.2.2 B) 
leading to formation of filopodia, lamellipodia, actin nodules and stress fibres, in a process 
known as spreading (Calaminus et al., 2008). This change in shape is driven by an increase in 
the rate of polymerisation of the platelet actin cytoskeleton, downstream of a signalling 
cascade initiated by binding of surface receptors to an agonist. 
 
While circulating in the blood, the platelet has a discoid shape. This shape is preserved by the 
platelet cytoskeleton which involves a spectrin-based membrane skeleton, a tightly coiled, 
circumambient band of microtubules and a rigid actin filament network. Upon activation of or 
adhesion of platelets, they undergo dramatic morphological changes, with the formation of 
filopodia protrusions, followed by lamellipodia formation before the platelet is fully spread, 
adopting a ‘fried-egg’ shape (Fig. 1.2.2 B). These morphological changes are as a result of the 
breakdown of the ring of microtubules and of polymerisation, branching and 
depolymerisation of the actin cytoskeleton, driving the formation of a variety of actin 
structures including, filopodia, actin nodules, lamellipodia and stress fibres. 
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Signalling across platelet receptors leads to the rapid activation of molecules that induce 
reorganization of the cytoskeleton. This, in turn, allows platelet aggregation, contraction, or 
spreading at sites of injury. A further function of the cytoskeleton is to bind these signalling 
molecules and recruit them to the required location for activation (Fox, 2001). 
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1.3 ACTIN CYTOSKELETON 
The actin cytoskeleton plays a vital role in maintaining the shape and integrity of the platelet 
in the high shear environment of the vascular system and mediating shape change once 
activated (Kobsar and Eigenthaler, 2006). While circulating in the blood, the platelet’s 
characteristic discoid shape is preserved by a rigid network of actin filaments throughout the 
cytoplasm (Boyles et al., 1985). When the platelet adheres to the extracellular matrix, ECM, 
the platelet shape change is induced by the massive reorganisation of the actin cytoskeleton 
(Hartwig, 1992). 
 
 
1.3.1 Actin 
Actin, a 42 kDa protein, is the most profuse protein in platelets, with approximately 2 million 
copies per cell and 40 % of which exists in a polymerised form consisting of 2000-5000 actin 
filaments (Hartwig and Italiano, 2006, Hartwig and Kwiatkowski, 1991). The rest remains in 
its monomeric form, globular (G-) actin, in the cytoplasm. Polymerisation of G-actin to 
filamentous (F-) actin is controlled by many actin binding and signalling proteins (Figure 
1.3.1). The type of actin structure formed with F-actin is dependent on the type of proteins 
present. 
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1.3.2 Actin polymerisation & depolymerisation 
G-actin binds to ATP or ADP. The conformation of the actin monomer is controlled by the 
process of ATP hydrolysis. Binding of ATP to G-actin, is not required for actin 
polymerisation but the conformation induced by ATP binding results in ATP-actin 
polymerising more readily than ADP-actin. Initiation of actin polymerisation is a spontaneous 
process wherein G-actin oligomerises, to form a trimer, if the monomer concentration is 
above the critical concentration (Carlier and Pantaloni, 1997). These initial actin filaments are 
highly unstable and require the presence of additional proteins for efficient nucleation and 
assembly of actin filament networks. These proteins include capping protein, ADP/cofilin, 
profilin, formins and Arp2/3 complex (Dos Remedios et al., 2003) 
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(Cooper, 2000) 
F-actin is polarised and its polarity is visualised via electron microscopy and is a result of 
myosin bound to the filaments which gives the appearance that it is coated with arrowheads 
that all align in one direction (Begg et al., 1978). This gives rise to their names as the pointed 
and barbed ends of the actin filament. The barbed end is bound with capping protein (Isenberg 
et al., 1980, Narita et al., 2006). The barbed end is arranged toward the plasma membrane 
while the pointed end is toward the cell interior. Actin filaments are polymerised by the 
addition of ATP-actin to the barbed end, as a result, the barbed end has a high concentration 
of ATP. Following polymerisation, the ATP is hydrolysed to ADP. Although dissociation of 
monomers occurs at both ends of F-actin, ADP-actin dissociates more readily than ATP-actin. 
As a result there is a net effect of depolymerisation at the pointed end. In a resting cell, stable 
actin filaments undergo continuous polymerisation and depolymerisation with a constant 
treadmilling of G-actin from the pointed end to the barbed end (Figure 1.3.2) (Bugyi and 
Carlier, 2010). To maintain this equilibrium, the pool of ATP actin is replenished by binding 
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of ADP-actin to profilin, a nucleotide exchange factor. Conversely, to ensure that not all of 
the ADP-actin is incorporated into F-actin, excess ADP-actin also binds to thymosin-β4 
thereby preventing nucleotide exchange (Carlier et al., 1993). 
 
When the cell is stimulated, there is an increase in barbed end formation brought about by 
uncapping or severing existing filaments and by de novo nucleation. This has the effect of 
increasing the rate of actin polymerisation. Actin binding proteins such as, profilin, cofilin, 
Arp2/3 and many others, together promote and rapid turnover of actin filaments and influence 
remodelling of the actin cytoskeleton required for cell motility and/ or shape change. 
 
 
1.3.3 Actin structures 
The remodelling of the actin cytoskeleton results in the formation of different actin structures. 
These actin structures include filopodia, lamellipodia, stress fibres, membrane ruffles, focal 
adhesions, podosomes, invadapodia and the platelet actin nodule. The structure formed is 
influenced by a variety of signalling pathways in response to stimulation of the cell. 
 
Filopodia 
Filopodia are thin membrane protrusions and consist of parallel bundles of 10-30 actin 
microfilaments which are held together by the actin binding proteins, such as fascins while 
ezrin, radixin and moesin (ERM) proteins link the cytoskeleton to the membrane (Figure 1.3.3 
A) (Mattila and Lappalainen, 2008). Filopodia are implicated in many different cellular 
processes, including cell migration, adhesion to the ECM, wound healing, neurite growth and 
as a sensor of chemoattractants, guiding the cell towards them (Faix and Rottner, 2006). 
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Within the filopodia structure, the F-actin is arranged with the barbed end at the membrane. 
As a result, actin polymerisation occurs at the tip of the filopodium and is most likely driven 
by formins (Mellor, 2010). 
 
 
(Mellor, 2010) 
Filopodia formation in platelets is driven by the Rho GTPases (Figure 1.3.3 B) in particular 
via CDC42 activation of Wiskott Aldrich Syndrome protein, WASp/ Arp2/3 pathway (Carlier 
et al., 1999). However, filopodia still form in WASp-/- platelets (Gross et al., 1999, Falet et 
al., 2002). Alternatively RIF activation of the formin mDia1 has been proposed as a CDC42-
independent pathway (Goh et al., 2011). In platelets, pathways other than Rif-mDia1 may 
play a role in filopodia formation (Goggs et al., 2013). Both pathways result in downstream 
actin polymerisation and hence filopodia formation. 
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Lamellipodia 
Lamellipodia consists of highly branched, short actin filaments and form a sheet-like structure 
in the gaps between filopodia (Figure 1.3.4 A) (Vinzenz et al., 2012). The 3D layer of cross-
linked actin filmaments is essential for cell spreading and motility. The branching is as a 
result of binding of Arp2/3 complex to F-actin, enabling nucleation of new actin filaments in 
that branch-off from existing filaments. The presence of Arp2/3 in cells is crucial for 
lamellipodia formation (Wu et al., 2012). 
 
 
(Cosen-Binker and Kapus, 2006) 
Similar to filopodia formation, lamellipodia formation in platelets is driven by Rho GTPases 
(Figure 1.3.4 B). Unlike filopodia, the main Rho GTPase implicated in lamellipodia formation 
is Rac1 which is activated by several platelet agonists, including, thrombin, fibrinogen, 
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collagen and ADP (McCarty et al., 2005). This results in actin polymerisation via downstream 
activation of Scar/Wave and Arp2/3 or via PAK and cofilin (Ibarra et al., 2005, Spence et al., 
2012, Aslan et al., 2013) 
 
Stress Fibres 
Stress fibres have a similar structural organisation to sarcomeres in muscle cells and contain 
non-muscle versions of proteins such as actin and myosin II (Figure1.3.5 A) (Pellegrin and 
Mellor, 2007). F-actin is cross-linked by binding of myosin II and α-actinin to form parallel 
microfilaments (Peterson et al., 2004). Stress fibres are implicated in tail retraction in 
migrating cells and also have a major role in generating contractile forces in tissues. Within 
the stress fibre, the orientation of F-actin is dependent upon the contractile properties required 
in the cells (Cramer et al., 1997). 
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Stress fibre formation in platelets is driven by the Rho GTPase RhoA. This either affects actin 
polymerisation via the formin mDia1 or Rho-associated protein kinase, ROCK/myosin II 
activation pathways (Figure 1.3.5 B) (Gao et al., 2009, Katoh et al., 2001). Both pathways 
result in polymerisation of actin and formation of stress fibres. 
 
Other specialised actin structures 
Other actin structures have also been described in spreading cells including, dorsal and 
peripheral ruffles, focal adhesions, podosomes and invadapodia (Figure 1.3.6): 
 
Dorsal and peripheral ruffles are similar to lamellipodia (Figure 1.3.6 A). The difference 
between ruffles and lamellipodia is that lamellipodia are forward-protruding structures that 
are weakly adhered to the substratum while ruffles protrude away from and are not adhered to 
the substratum (Abercrombie, 1980). There are two types of membrane ruffles; dorsal and 
peripheral ruffles (Abercrombie et al., 1970). Dorsal ruffles are found behind the lamellipodia 
leading edge and are often associated with receptor internalisation (Hoon et al., 2012). 
Peripheral ruffles are usually found at the leading edge of lamellipodia and play a role in cell 
motility (Suetsugu et al., 2003). However, neither peripheral nor dorsal ruffles have been 
reported in platelets. 
 
Focal adhesions are actin-rich structures which connect stress fibres to the substratum and as 
such contain many actin associated proteins linking the stress fibres to the substratum via 
integrins (Figure 1.3.6 B). These proteins include vinculin, talin, paxillin and focal adhesion 
kinase, FAK (Kanchanawong et al., 2010). They are often located at stress fibre termini. 
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(Linder and Aepfelbacher, 2003, Linder et al., 2011, Kanchanawong et al., 2010) 
Focal adhesions serve as a point from which the cell can transmit internally generated force to 
the extracellular matrix, ECM, and vice versa (Wang and Suo, 2005). The presence of force, 
generated by the actin cytoskeleton, inside the cell drives the formation of the focal adhesion 
complexes. Focal adhesions have been reported in platelets spread on fibrinogen and glass 
(Leng et al., 1998, Cerecedo et al., 2006) 
Chapter 1 – General Introduction 
Page | 20 
Podosomes are actin-rich structures involved in adhesion which were first identified in 
osteoclasts (Marchisio et al., 1984). They are a punctate actin structure which consists of an 
actin core surrounded by a ring of actin-associated proteins linking the actin filaments to 
integrins and consequently to the ECM (Figure 1.3.6 C). These proteins include, vinculin, 
talin and paxillin (Linder and Kopp, 2005). Super-resolution technology has found that the 
podosomes are polygonal in shape (Cox et al., 2012). The podosomes are often found grouped 
together in large numbers, forming a rosette structure. 
 
Podosomes are adhesive structures and are comprised of many of the same proteins that are 
found in focal adhesions, including talin, vinculin, paxillin and Src family kinases, SFKs. 
However, the presence of Wiskott Aldrich Syndrome protein, WASp, is unique to podosomes 
and therefore distinguishes them from other actin structures (Block et al., 2008). Podosomes 
are also thought to play a role in cell invasion via matrix degradation through secretion of 
matrix metalloproteins, MMPs, from the podosome core (Gawden-Bone et al., 2010, Linder, 
2007, Schachtner et al., 2013). Although podosomes are found in the platelet precursor, the 
megakaryocyte, they have not been identified in platelets. 
 
Invadopodia are actin-rich structures which protrude from the cell. They consist of a F-actin 
core, microtubules and several actin associated proteins including, formins, cortactin and 
fascins (Figure 1.3.6 D) (Schoumacher et al., 2010, Linder, 2007). The invadopodia base has a 
similar branched actin structure to podosomes from which parallel bundles of actin, similar to 
those in filopodia, protrude. 
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Similarly to podosomes, invadopodia degrade ECM by secretion of MMPs (Linder et al., 
2011). However, unlike podosomes, they are mainly found in cancer cells, its elongated 
protrusions project in to the ECM and they are more efficient at degrading the substratum 
(Linder, 2007). However, invadopodia have not been reported in platelets. 
 
 
Actin nodules 
While filopodia, lamellipodia, and stress fibres have been well described in platelets, the actin 
nodule was first described in 2008 by Calaminus et al (Calaminus et al., 2008). The actin 
nodules are punctate areas of actin staining, present in the early stages of platelet spreading 
but absent in fully spread platelets with stress fibres (Figure 1.3.7 A-B). Actin polymerisation 
is required for nodule formation. Immunohistochemistry studies revealed that the actin 
nodules co-localised with many of the proteins involved in regulating the actin cytoskeleton 
including Rac, Fyn, Arp2/3 complex, cortactin, talin, and β1 and β3-integrin subunits. 
Additional proteins that were found to co-localise with actin nodules include, adhesion- and 
degranularion-promoting adapter protein, ADAP, and vinculin (Kasirer-Friede et al., 2010). 
Although, in ADAP
-/-
 platelets nodules still formed but they did not co-localise with vinculin. 
Vinculin deficient platelets still formed actin nodules which suggest that vinculin is not 
required for actin nodule formation but its presence may help maintain the interaction 
between the cytoskeleton and the ECM when exposed to mechanical forces (Mitsios et al., 
2010). 
 
Focal adhesions and podosomes have a similar circular appearance to that of the actin nodule; 
however, it is not thought that the actin nodule represents either of these actin structures: 
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While focal adhesions form at the ends of stress fibres, the actin nodule is not present in 
platelets with stress fibres. Moreover, the rosette structure and presence of an enriched actin 
core and outer ring, the main characteristics of a podosome, are not apparent in actin nodules. 
Consequently, the actin nodule appears to be a novel platelet actin structure. 
 
 
 
The actin nodules appear to be unrelated to filopodia formation since filopodia are found in 
platelets with or without actin nodules. However, the authors propose that the time course and 
the type of proteins that associate with the actin nodule allude to it playing a part in the 
process of lamellipodia formation (Calaminus et al., 2008). Additionally, it is supposed that 
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the actin nodules may play an important function in the actin dynamics of early spreading 
platelets 
 
Although it was found that Src did not co-localise with nodules, Kasirer-Friede et al, found 
that the nodules co-localised with activated Src under flow conditions (Calaminus et al., 2008, 
Kasirer-Friede et al., 2010). Furthermore, under shear stress they noted that nodules were 
persistent throughout the cells, even when fully spread but lacking stress fibres (Figure 1.3.7 
C). Thus suggesting the nodules may have a further role in anchoring the platelets to a surface 
when under shear stress. 
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1.4 VISUALISATION OF THE ACTIN CYTOSKELETON 
Fixed cell imaging studies have provided a great deal of information about platelet shape 
change but the role of actin, and in particular that of the actin nodule, in this can only be 
thoroughly studied through live-cell imaging. Reliable visualisation of the actin cytoskeleton 
has historically been achieved by injection of fluorescently labelled actin or fluorescently 
labelled phalloidin. The development of fluorescent proteins, most notably the green 
fluorescent protein, GFP and its colour analogues, enabled expression of GFP fusion proteins 
in transfected cells. These fusion proteins included actin and actin binding proteins such as 
moesin and utrophin. 
 
 
1.4.1 Phallotoxins 
Phalloidin is a naturally occuing bicyclic heptapeptide found in death cap mushrooms 
(Amanita phalloides). It binds with high affinity (~30 pM) to F-actin (Faulstich et al., 1977), 
although, this affinity is somewhat reduced when phalloidin is fluorescently labelled (~270 
nM) (Wulf et al., 1979). In particular it binds at the interface between F-actin subunits, 
effectively locking them together (Vandekerckhove et al., 1985). This binding inhibits ATP 
hydrolysis and prevents depolymerisation of F-actin which has the effect of stabilising actin 
filaments (Barden et al., 1987). This stabilisation of F-actin is irreversible and leads to cell 
death, therefore it is more suited for use with fixed cells. Phalloidin is cell impermeant so 
uptake into cells has relied on membrane permeablisation, microinjection, electroporation or 
scrape loading (Small et al., 1999). However, cell permeant versions are now available. The 
use of phalloidin for live cell imaging is limited to injectable large cells. Phalloidin injected 
into live cells was found to disrupt actin dynamics consequently affecting cell growth and 
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motility (Wehland et al., 1977). However, when used in low concentrations, it can be used to 
visualise actin in living cells (Wehland and Weber, 1981). 
 
 
1.4.2 Fluorescent proteins 
The discovery and development of fluorescent proteins, most notably the green fluorescent 
protein, GFP, drastically improved the ability to label proteins in intact cells. GFP is a 238 aa, 
26.9 kDa protein derived from the Aequorea victoria jellyfish (Shimomura et al., 1962). It 
exhibits bright green fluorescence upon exposure to blue light. Since it was first cloned and 
expressed in cultured cells it has become one of the most widely used proteins in cell biology 
(Prasher et al., 1992, Chalfie et al., 1994). Its most common use is as a fusion tag to proteins 
of interest to monitor their cellular localisations. GFP has been targetted to every major cell 
organelle and its size and shape nor the differing environments within cells and their organelle 
appear to affect GFP. Additionally GFP has been expressed ubiquitously in whole animal 
models (Okabe et al., 1997). However use of GFP fusion proteins is limited to cells which can 
be transfected or can undergo microinjection. 
 
Actin-GFP 
Expression of GFP-actin fusion protein has been used to study live cell actin dynamics 
(Choidas et al., 1998, Calaminus et al., 2008). Although GFP-actin enables labelling of the 
actin cytoskeleton, it has several disadvantages. This includes the requirement for low 
expression levels to reduce background staining by GFP-actin monomers and to provide a 
large pool of non-labelled actin to compensate for the impairment in functionality of GFP-
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actin (Westphal et al., 1997, Yamada et al., 2005). Additionally, the expression of GFP-actin 
has been shown to affect cellular actin dynamics (Feng et al., 2005, Deibler et al., 2011). 
 
Actin binding proteins/ domains 
In place of GFP-actin fusion protein, other GFP-fusion proteins have been utilised to study 
live cell actin dynamics. Actin binding proteins or binding domains GFP-fusions used have 
included, moesin, LimeE, ABP120, ABP140 and utrophin (Edwards et al., 1997, 
Bretschneider et al., 2004, Socol et al., 2010, Pang et al., 1998, Yang and Pon, 2002, Burkel et 
al., 2007). While all have successfully been used to monitor actin dynamics in live cells, the 
fusion proteins may still affect actin dynamics because of their larger size and the likely 
competition for binding with their unlabelled, endogenous homologue. While all have 
successfully been used to monitor actin dynamics in live cells, the fusion proteins may still 
affect actin dynamics because of their larger size and the likely competition for binding with 
their unlabelled, endogenous homologue. 
 
 
1.4.3 Lifeact 
Total internal reflection fluorescence, TIRF, microscopy studies of the actin binding 
capabilities of Actin Binding Protein 140, ABP140, revealed that the protein’s first 17 amino 
acids were all that were required to efficiently bind to actin (Riedl et al., 2008). The peptide 
sequence of those first 17 amino acids, referred to as ‘Lifeact’, were found to be absent from 
other organisms despite being highly conserved among close relatives of Saccharomyces 
cerevisiae. Riedl et al assert that its small size and lack of endogenous analogous sequences 
make it an attractive alternative for actin labelling in higher eukaryotic cells (Riedl et al., 
Chapter 1 – General Introduction 
Page | 27 
2008). Additionally, Lifeact was found to have a lower affinity for F-actin (1.3 μM) than 
phalloidin (30 pM) which may attribute to Lifeact appearing to leave actin polymerisation and 
depolymerisation unaffected (Riedl et al., 2008, Faulstich et al., 1977). Although over 
expression of Lifeact has been shown to adversely affect actin dynamics, when compared 
with cells expressing actin-GFP, actin dynamics are dramatically less affected by its presence 
(van der Honing et al., 2011, Deibler et al., 2011) 
 
 
Phalloidin has been used extensively in platelets to image the actin cytoskeleton of fixed cells. 
Additionally, GFP-actin and GFP-lifeact have been used to study live cell actin dynamics in 
platelets from mouse models expressing the GFP fusion proteins (Calaminus et al., 2008, 
Schachtner et al., 2012). However, these labelling methods have fundamental drawbacks for 
studying actin dynamics in spreading human platelets: Firstly, human platelets are anucleate, 
so it is not possible to transfect the cells which rules out the possibility of using the 
fluorescent protein fusion proteins. Secondly, the platelet membrane is extremely sensitive to 
external stimuli. Therefore, introduction of fluorescent labels via techniques such as 
microinjection, scrape loading or detergent induced membrane permeablisation would not be 
possible.  
 
Instead this project aims to introduce fluorescently labelled Lifeact peptide into human 
platelet using an intracellular delivery moiety, in order to study actin nodule dynamics. The 
small size of the Lifeact peptide makes it relatively easy and cheap to manufacture. 
Additionally, access to platelets from Lifeact-GFP mouse model would serve as a suitable 
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comparison; firstly for validation of successful cellular uptake and nodule labelling and 
secondly for fundamental studies on the actin nodule and its role in platelet function. 
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1.5 INTRACELLULAR DELIVERY OF MOLECULES 
There are many different methods of introducing imaging labels, such as Lifeact, or other 
molecules into cells. Methods of achieving this include; transfection, microinjection, 
membrane permeablisation, exploitation of the cells natural endocytic pathways, cell 
penetrating peptides, nanoparticles or liposomes. 
 
 
1.5.1 Overview in platelets 
Due to the platelet’s anucleate state and reactivity to external stimuli, the use of transfection 
or microinjection to deliver imaging labels are not suitable. Even though transgenic mouse 
models which express GFP fusion proteins, including GFP-Lifeact, are available, they are 
costly and time consuming to generate and murine cells are not always suitable substitutes for 
human cells (Okabe et al., 1997, Riedl et al., 2010, Lin, 2008). Consequently, in platelets, 
membrane permeablisation is the main method of introducing imaging labels to cells. 
However, permeablisation of platelets results in rapid loss of intracellular contents as a result 
of the high surface area to volume ratio so is reserved for fixed cell samples only 
(Flaumenhaft, 2004). 
 
 
1.5.2 Other methods 
In the fields of drug delivery and diagnostics a number of other intracellular delivery methods 
are being investigated to facilitate delivery of drugs or imaging agents including 
nanoparticles, liposomes and cell penetrating peptides. 
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Nanoparticles 
There are many different types of nanoparticles including polymers, dendrimers, micelles, 
liposomes and metallic. These nanoparticles either encapsulate the therapeutic or imaging 
agent or provide a surface for their attachment. Cellular uptake of these nanoparticles is most 
likely via endocytosis although passive uptake of nanoparticles is also thought to occur 
(Treuel et al., 2013, Verma et al., 2008, Lin et al., 2010). Additionally, it is proposed that in 
cancerous tumours, the increased permeability of the cells membranes enables non-endocytic 
uptake of nanoparticles (Maeda et al., 2013, Maruyama, 2011, Wang et al., 2012, Wolinsky et 
al., 2012, Haley and Frenkel, 2008). 
 
Nanoparticles have been shown to enter a variety of cells on a timescale of 2 – 48 hours of 
incubation (Bickford et al., Chung et al., Li et al., 2010, Wang et al., 2009). Nanoparticle 
carriers which are taken up via endocytosis, result in the imaging label or drug residing in 
vesicles outside of the cytoplasm. Those that passively move across the cell membrane into 
the cytoplasm can result in disruption to the cell membrane (Leroueil et al., 2008). Therefore, 
there is a lot of scepticism towards the use of nanoparticles as intracellular, cytoplasmic 
delivery vectors (Nativo et al., 2008). 
 
Nanoparticles have been used to label whole platelets or to induce platelet aggregation 
following interaction with the platelet membrane (Woolley et al., 2013, Dobrovolskaia et al., 
2012). Additionally, nanoparticles are increasingly explored for diagnostic and drug delivery 
potential, their interaction with and their effect on the blood cells, including platelets requires 
investigation (Semberova et al., 2009, Lacerda et al., 2011, Ali et al., 2013, Ilinskaya and 
Dobrovolskaia, 2013a, Ilinskaya and Dobrovolskaia, 2013b). However, they are unlikely to be 
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suitable to deliver imaging labels, such as Lifeact, into the cytoplasm of human platelets 
without affecting the cell. 
 
 
Cell-penetrating peptides 
Another approach is to utilise the membrane penetrating properties of some peptides. These 
peptides are most commonly referred to as cell-penetrating peptides, CPP, but are also known 
as protein transduction domain, PTD, or membrane translocatting sequence, MTS. CPPs 
usually consist of fewer than 30 aa residues and are able to deliver cargo molecules into cells 
(Lundberg and Langel, 2003). There are many types of CPP currently under investigation 
(Jones and Sayers, 2012) but the most studied are HIV-Tat peptide (Chauhan et al., 2007), 
penetratin (Derossi et al., 1994)  which is also known as pAntp, transportan (Pooga et al., 
1998) and poly-L-lysine or poly-L-arginine, PLL and PLA, respectively (Futaki et al., 2007, 
Reuter et al., 2009, Schmidt et al., 2010).  . Although, initially assumed that direct transport of 
these peptides across the lipid bilayer was the mechanism of their uptake, it is now thought 
their uptake may be by endocytosis (Richard et al., 2003, Chauhan et al., 2007, Futaki et al., 
2007). A range of cargo molecules have been delivered using CPPs including small peptides, 
oligonucleotides and nanoparticles (Abes et al., 2007, Liu et al., 2013, Zhang et al., 2013, 
Zhang et al., 2011, Schwarze et al., 1999). In platelets CPPs have been used to deliver 
inhibitors or actually inhibit platelet receptors (Bernard et al., 2009, Covic et al., 2002a, Covic 
et al., 2002b, David et al., 2006, Dimitriou et al., 2009) 
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1.5.3 pH (low) insertion peptide 
Recently another method of cellular delivery has been reported, in the form of a peptide called 
pH (low) insertion peptide, pHLIP (Reshetnyak et al., 2006). pHLIP spontaneously inserts 
itself into the lipid bilayer upon a decrease in pH, thereby translocating its cargo molecules 
into the cell. It is not clear at present if pHLIP would be categorised as a CPP (Jones and 
Sayers, 2012). 
 
pHLIP, is derived from the C-helix of the transmembrane bacteriorhopsin, BR, protein. The 
C-helix, unlike the other six helices of BR, was found to have unique properties, including its 
solubility and pH controlled membrane insertion (Hunt et al., 1997a). Transmembrane helices 
are ordinarily characterised by their sequences of approximately twenty hydrophobic amino 
acids giving rise to water insolubility, the C-helix, however, was found to be both soluble in 
an aqueous and lipid environment (Reshetnyak et al., 2007, Hunt et al., 1997b). The 
modification of the peptides hydrophobicity by pH is due to the presence of two aspartic acid 
residues. In the native BR, these residues play a key role in proton transport, with one residue 
acting as the donor and the other, the acceptor (Bousche et al., 1991a, Bousche et al., 1991b, 
Bousche et al., 1992). However, Hunt et al found that the protonation of one or both of these 
residues, in a mildly acidic environment, resulted in enhancement of the peptide 
hydrophobicity, thereby enabling spontaneous membrane insertion (Hunt et al., 1997b, Hessa 
et al., 2005). Furthermore, it was found that this pH-dependent alteration in solubility is also 
strictly dependent on the presence of phospholipids. 
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At neutral or slightly alkaline pH (pH 7 - pH 8), BR C-helix and pHLIP exist as an 
unstructured peptide both in solution (State I) and when it associates with lipid membranes 
(State II) (Figure 1.5.1). At acidic pH (<pH 6.5), pHLIP forms an α-helix and spontaneously 
inserts itself, unidirectionally, across the lipid bilayer (State III). Whereby, pHLIP’s polar C-
terminus is moved into the cytoplasm while its N-terminus remains outside (Reshetnyak et al., 
2007). In all three states pHLIP is monomeric at concentrations less than 7 μM (Reshetnyak et 
al., 2007). The insertion process is completely reversible upon restoration of neutral pH 
(Reshetnyak et al., 2006). 
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pHLIP is a 38 amino acid peptide that consists of 22 amino acids from the transmembrane 
section of the BR C-helix and two flanking sequences (Figure 1.5.2) (Andreev et al., 2009). It 
is relatively rich in acidic residues (four aspartic acid (Asp) and two glutamic acid (Glu) 
residues and the C-terminal carboxy group) and their combined negative charge forms a large 
energy barrier (~22 kcal/mol) to peptide insertion (Barrera et al., 2011). Binding to the lipid 
membrane and subsequent peptide insertion, at low pH, are accompanied by energy release 
(~6-7 kcal/mol and ~1.8 kcal/mol, respectively) suggesting that a large proportion of these 
groups need to be protonated in order for insertion to occur. It has been found that the two 
transmembrane Asp residues (Asp14 and 25) are protonated first inducing deeper penetration 
of the peptide in the membrane, accompanied by α-helix formation (Figure 1.5.3) (Musial-
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Siwek et al., 2010, Karabadzhak et al., 2012). This agrees with an earlier finding that 1.5 - 1.8 
protons are involved in the protonation step (Reshetnyak et al., 2008). However, the other 
charged residues at the C-terminus are unlikely to be protonated at the same time, thus 
opposing the peptide insertion and driving formation of intermediate structures observed by 
Andreev et al (Andreev et al., 2010). Karabadzhak et al, propose that this rate limiting step 
could be overcome in order to relieve the instability and tension that the partial insertion 
exhibits on the lipid bilayer (Karabadzhak et al., 2012).  
 
Removal of pHLIP from the lipid bilayer is via a different mechanism which occurs more 
rapidly than insertion (Figure 1.5.3) (Andreev et al., 2010). Increasing the extracellular pH 
results in deprotination of the charged residues buried deep in the membrane hydrophobic 
core thus destabilising the helix (Barrera et al., 2011). The energy from the destabilising 
process fuels removal of pHLIP from the membrane. In the lipid palmitoyl oleyl phosphatidyl 
choline, POPC, vesicles, the removal process is complete in approximately 100 ms (Andreev 
et al., 2010). 
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pHLIP has dual cargo delivery properties: Cargo molecules attached to its N-terminus are 
delivered to the cell surface and then tethered there in low pH conditions (Figure 1.5.4 A). 
This is particularly useful for enabling imaging of cell membranes or tissue margins and has 
been shown to have potential diagnostic possibilities for positron emission tomography (PET) 
and near-infrared (NIR) imaging technologies (Reshetnyak et al., 2011, Segala et al., 2009, 
Andreev et al., 2007, Vavere et al., 2009, Mata et al., 2007). Additionally, attachment of cargo 
molecules to the C-terminus of pHLIP enables cytoplasmic delivery of cargo molecules 
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(Figure 1.5.4 B). If that cargo molecule is conjugated to pHLIP via a disulphide bond, the 
reducing environment of the cell cleaves the bond, releasing the cargo into the cell 
(Reshetnyak et al., 2006). C-terminally conjugated cargo enables cytoplasmic delivery and 
release of molecules such as drugs, inhibitors or molecular labels (Moshnikova et al., 2013, 
Wijesinghe et al., 2011, An et al., 2010). Thus pHLIP can be used as both an intracellular 
cargo/drug delivery system and for labelling cell/ tissue margins. 
 
 
 
As a cell labelling mechanism, many different types of imaging labels have been conjugated 
to pHLIP’s N-terminus which demonstrates its suitability for a variety of medical imaging 
techniques. These have included; near-infrared, NIR, labels such as Cy5.5 and Alexa750 
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(Segala et al., 2009, Reshetnyak et al., 2011), 
64
Cu-DOTA and [
18
F] for positron emission 
tomography, PET, (Vavere et al., 2009, Daumar et al., 2012), gold nanoparticles or 
fluorescent labels for optical imaging of tissue sections (Yao et al., 2012, Sosunov et al., 
2013) and 
99
Tc labels for single photon emission computed tomography (Macholl et al., 2012, 
Weerakkody et al., 2013). 
 
pHLIP has been shown to deliver a variety of molecules into cells, including peptide nucleic 
acid, PNA, (~2.5 kDa), cyclic peptides (<850 Da), fluorescent dyes such as dansyl, α-
amanitin and phalloidin (Reshetnyak et al., 2006, Thevenin et al., 2009). However, the type of 
C-terminus conjugated cargo for cytoplasmic delivery is limited by the cargo’s 
hydrophobicity. The more hydrophobic the cargo molecule, the more likely it will be 
translocated across the lipid bilayer by pHLIP. For instance, phallocidin is a highly polar 
molecule (logP = -1.6) but was not delivered to the cytoplasm of cells when conjugated via a 
disulphide bond to the C-terminus of pHLIP (Wijesinghe et al., 2011). Upon modulation of 
the polarity of phallacidin by addition of hydrophobic side chide chains of varying carbon 
length, increased cellular uptake of phallacidin was observed (30% for logP = -0.74, 70% for 
logP = -0.09). These results demonstrate the importance of the cargo polarity when selecting 
potential molecules for cytosolic delivery by pHLIP. To enable delivery of polar molecules, 
liposomes, which are composed of lipids conjugated to pHLP’s N-terminus, take advantage of 
the ability of pHLIP to interact with lipid membranes and as a result promote fusion of 
liposomes to the cell membrane (Yao et al., 2013). 
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(Reshetnyak et al., 2006, Reshetnyak et al., 2011, Segala et al., 2009)
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Biological applications of pHLIP have focused on exploiting the low pH conditions that arise 
as a symptom of some pathological diseases (Figure 1.5.5). Such diseases include cancerous 
tumours (Stubbs et al., 2000), atherosclerotic plaques (Naghavi et al., 2002), ischemia (Cobbe 
and Poole-Wilson), inflammation (Kellum et al., 2004), infection (Kielian and Jungerwirth, 
1990) and trauma-induced tissue damage (Johansson et al., 2012). The pH-dependent 
insertion properties of pHLIP make it an ideal diagnostic tool and drug delivery system for 
treating such conditions. Successful detection of cancerous tumours, metastases, ischemic 
tissue and H1N1 virus damaged alveolar  has been demonstrated in a variety of mouse models 
(Reshetnyak et al., 2011, Segala et al., 2009, Vavere et al., 2009, Sosunov et al., 2013, 
Daumar et al., 2012, Moshnikova et al., 2013, Li et al., 2013). Retention of pHLIP in normal 
tissues, excluding the kidneys, is minimal (Andreev et al., 2007). Although, membrane 
disruption of red blood cells by pHLIP in neutral conditions was observed. The sequence of 
pHLIP has been tuned to increase targeting efficiency and reduce retention in non-target cells 
and tissues (Weerakkody et al., 2013). 
 
pHLIP uptake on a cellular level has been investigated for cell cultures with artificially 
lowered environmental pH (Reshetnyak et al., 2006, An et al., 2010, Yao et al., 2012, 
Moshnikova et al., 2013). These studies have demonstrated that pHLIP is able to deliver 
cargo molecules and label cells. Additionally, the effect of pHLIP on cells was determined to 
be minimal; no leakage of cell contents which is indicative of retention of membrane integrity 
and no apparent effect on cell numbers (Reshetnyak et al., 2006). 
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Its properties, including small size, solubility, pH-dependent membrane insertion and its 
formation of a transmembrane helix, make it an attractive moiety for studying transmembrane 
protein properties. Additionally, this peptide has the potential to act as a delivery system for 
drug molecules, imaging probes or other cargo molecules targeting low pH environments 
which can be generated artificially or found in pathological conditions. pHLIP has the further 
advantage that cargo uptake would not be reliant on endocytic pathways which are required 
for the many other delivery systems discussed above. These properties of pHLIP make it an 
attractive delivery method for use in platelets. To date, pHLIP has not been used as a delivery 
agent for assisting in further understanding of cellular workings or to enable elucidation of 
roles of structures or protein complexes inside cells. This project aims to develop pHLIP as a 
delivery vector to deliver a variety of imaging labels to enable imaging of actin nodule 
dynamics in human platelets. 
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1.6 IMAGING MODALITIES 
1.6.1 Epifluorescence microscopy 
Epifluorescence microscopy is an optical microscopy technique which exploits the 
phenomenon of fluorescence or phosphorescence. Fluorescence occurs when a fluorophore 
absorbs a photon and then emits a photon of lower energy and therefore, higher wavelength 
than the excitation light. This red-shift enables the separation of the excitation and emission 
light through the use of filters. A schematic diagram of the principle of epifluorescence 
microscopy is shown below (Figure. 1.6.1). 
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Epifluorescence microscopy is widely used for imaging fluorescent labels in cells and is 
suitable for both live cell and fixed cell samples. However, its main disadvantage is the 
inability to differentiate between fluorophores in different focal planes. Consequently, two 
different fluorophores which are in different focal planes appear to originate from the same 
point and could be misinterpreted as being co-localised. 
 
 
1.6.2 Confocal fluorescence and reflection microscopy 
Confocal fluorescence microscopy has similar illumination principles as fluorescence 
microscopy, except it is able to eliminate out-of-focus emitted light through the use of a 
pinhole, thereby enabling imaging in a variety of focal planes (Figure 1.6.2). Imaging in 
different focal planes allows for three dimensional reconstruction of the sample. There are 
several types of confocal microscope, namely laser scanning confocal microscope, LSCM, 
and spinning disk confocal microscope, SDCM. LSCM is the most commonly used type, 
where by a laser is scanned across a sample, while SDCM has a rotating array of microlenses 
to focus the beam and a simultaneous rotating array of pin holes (Stephens and Allan, 2003). 
SDCM enables rapid live cell imaging, with markedly reduced photobleaching but it is slow 
to change between limited laser lines, reducing its use in two colour studies, and it cannot be 
used for techniques such as fluorescence recovery after photobleaching, FRAP, both of which 
can be done using LSCM. 
 
LSCM also enables confocal reflection microscopy (CRM), a technique whereby light 
reflected from ~10 nm either side of the excitation wavelength. Due to the interference pattern 
of incidence and reflected light, areas which are closer to the surface of the coated coverslip 
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appear dark while those further away are lighter (Curtis, 1964, Radler et al., 1995). Specialist 
microscopes are available which suppress stray reflections enabling imaging of ultrathin 
optical sections of approximately 5 nm (Filler and Peuker, 2000). 
 
 
 
This technique can therefore be used to image membrane morphology at the interface between 
the membrane and the coverslip (Limozin and Sengupta, 2009, Verschueren, 1985). It has 
been previously used to determine close platelet/surface contact areas of platelets under static 
and flow conditions (Lee et al., 2012, Kasirer-Friede et al., 2010). Additionally, this technique 
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enables simultaneous visualisation of the whole platelet via CRM and the fluorescence image. 
Thereby providing more accurate cellular localisation of the fluorescence signal in platelets 
than would otherwise be achieved using a conventional LSCM with transmitted light imaging 
capabilities. 
 
A further application of CRM is imaging of gold nanoparticles. Gold nanoparticles of ~13 nm 
diameter have been shown to scatter light of around 600 nm. Using CRM with 633 nm laser 
can enable imaging of nanoparticles in cells and has been demonstrated in fixed cell samples 
(Kah et al., 2008, Bickford et al., 2010).  
 
 
1.6.3 Total internal reflection fluorescence microscopy 
Total internal reflection fluorescence (TIRF) microscopy permits imaging at the cell 
membrane–coverslip interface. This is possible because the excitation light is angled such that 
the light will be reflected back from the interface between the glass coverslip and the cell 
medium, this phenomenon is known as total internal reflection. Since light cannot become 
discontinuous at a boundary, an evanescent wave of light is generated which exponentially 
decays with distance travelled (Figure 1.6.3). This provides illumination at a distance of 
between 100 nm and 200 nm from the coverslip (Millis, 2012). The angle required for total 
internal reflection to occur is greater than the critical angle, θc. The critical angle is dependent 
on the refractive indexes of the two surfaces, the glass coverslip and the cell medium, and 
defined as: 
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This technique has the advantage of only illuminating fluorophores at less than 100 nm from 
the coverslip, therefore, removing the out-of-focus light that is usually present in fluorescent 
microscopy techniques. TIRF also permits imaging events at the cell surface, including cell 
motility and attachment events. It has also been reported that by adjusting the illumination 
angle enables imaging events at both the basal and the apical membrane (Fan and Jin, 2007). 
This is a particularly useful technique for imaging platelet spreading dynamics which involve 
adhesion to the surface and spreading across the surface mediated by surface receptor binding 
events (Schoenwaelder et al., 2010, Okamura et al., 2011). 
 
Additionally TIRF microscopy can be combined with other imaging techniques such as 
confocal or epifluorescence microscopy to enable imaging of events occurring at the cell 
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surface and throughout the rest of the cell (Pitkeathly et al., 2012). The combination of TIRF 
and epifluorescence microscopy, either simultaneously or sequentially, has proven useful in 
studying endocytosis event enabling tracking of vesicles and their constituents from the cell 
membrane into the cell (Merrifield et al., 2002, Lee et al., 2006). 
 
 
1.6.4 Transmission electron microscopy 
Transmission electron microscopy (TEM) enables high resolution imaging of fixed samples 
using an electron beam to generate the image. High energy electrons are fired at ultra thin 
specimens interacting with the sample as they are transmitted through it. It is this interaction 
that is used to generate an image. The resolution achieved can be as low as ~50 pm (Erni et 
al., 2009). TEM has applications across many disciplines, including in cell biology and in the 
determination of nanoparticles size distribution. 
 
Biological samples for TEM have to undergo a long and complex preparation process, in 
comparison to light microscopy samples. It includes fixation, dehydration, embedding, 
sectioning, mounting on grids and staining with heavy metals such as uranyl acetate or lead 
citrate to provide contrast. 
 
TEM has several disadvantages, including preparation required, it can only be used for fixed 
samples, is more expensive than light microscopy techniques, only a small field of view so 
samples may not be characteristic of the whole sample and potential of damaging biological 
samples by the high energy beam. Despite these drawbacks, the high resolution afforded by 
the use of TEM makes it an attractive imaging modality for elucidating cellular structures 
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such as the open canalicular system and the cytoskeletal system in platelets (White and 
Clawson, 1980, Loftus et al., 1984, Yoshikawa, 1991). Immunogold labelling has enabled 
imaging of localisation of cellular proteins due to the high contrast provided by the gold label 
bound to an antibody of choice. 
 
As such TEM will allow for determination of, firstly, the presence of gold nanoparticles in 
cell, demonstrating the ability of pHLIP as a delivery agent. Secondly, it will enable imaging, 
with high spatial resolution the localisation of these nanoparticles inside the cell and, as a 
result, direct measurement of the localisation of the protein and or structure the nanoparticles 
have been synthesised to bind to, for instance the actin cytoskeleton if coated with Lifeact. 
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1.7 MICROSCOPY LABELS 
1.7.1 Fluorescent & luminescent labels 
Organic fluorophores such as, fluorescein and Rhodamine, are widely used as labels in 
fluorescence microscopy. However, their fluorescence is often quenched following 
conjugation to proteins, is pH sensitive and they are not particularly photostable (Brunner et 
al., 1998, Singer and Johnson, 1997). This has led to the synthesis of other dyes such as Alexa 
dyes which are more stable, pH insensitive, exhibit more intense fluorescence and have wide 
variety of colours which are suitable for common excitation sources (Panchuk-Voloshina et 
al., 1999). 
 
Lanthanide ions are usually referred to as luminescent rather that fluorescent labels. This is 
because fluorescence refers to spin allowed singlet-to-singlet emission taking 10
-6
 to 10
-12
 
seconds. However, lanthanide emission is as a result of f-f transitions which are forbidden 
resulting in lifetimes in the μs to ms range. As a result, direct excitation of the lanthanide ion 
is inefficient so excitation is usually achieved through complexation with a ligand. 
 
The type of complex used can be used to tune the coordination and photophysical properties 
of a lanthanide (Charbonniere et al., 2008, Charbonniere et al., 2007, Andreiadis et al., 2009). 
Since the coordination chemistry of the lanthanides is similar across the group, the lanthanide 
can be altered to suit the required electromagnetic or paramagnetic properties (Lewis et al., 
2012). For instance, Sm
3+
, Eu
3+
, Tb
3+
 and Dy
3+
 emit in the visible range while Pr
3+
, Nd
3+
, 
Ho
3+
, Er
3+
 and Yb
3+
 emit in the near-infra red, NIR, and Gd
3+
 is highly paramagnetic. The 
conjugation to a ligand also helps to prevent quenching of lanthanide luminescence in 
aqueous solutions. Furthermore, these complexes can be designed to facilitate targeting of the 
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lanthanide complexes to specific organelle and to signal information about the environment 
(Montgomery et al., 2009). 
 
 
 
The advantage of using lanthanides over organic fluorophores include, their visible, narrow 
band-width luminescence, large stokes shifts and long lifetimes (Figure 1.7.1). In addition, 
emission can be turned by utilising different lanthanides, which can also tune the magnetic 
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properties of the label. The long lifetimes make them suitable for time-gated fluorescence 
imaging which enables elimination of autofluorescence signals. However, they have limited 
brightness and excitation and emission ranges often mean they are not suitable for use with 
conventional microscope systems. 
 
 
1.7.2 Gold nanoparticles 
Gold nanoparticles, AuNP, are attractive for use in biological and biomedical applications due 
to their optical properties, their bioinertness and they are not toxic (Ghosh et al., 2010). Their 
potential applications include drug carriers, labelling and tracking agents, vectors for gene 
therapy and magnetic resonance imaging (MRI) contrast agents (Thanh and Green, 2010). 
 
Formation of gold colloids involves the reduction of tetrachloroauric acid, usually following 
one of three methods: (1) Turkevich citrate method, (2) citrate-tannic acid method and (3) 
Brust-Schiffrin alkane-thiols method (Turkevich et al., 1951, Brust et al., 1994, Mühlpfordt, 
1982). The simplest method is the Turkevich method which involves the reduction of 
tetrachloroauric acid with trisodium citrate, the mechanisms of which have been investigated 
widely (Grabar et al., 1995, Kimling et al., 2006, Frens, 1973). Nanoparticle size is controlled 
by the amount of reducing agent used (Kumar et al., 2007). 
 
The tuneable size and electron density of AuNPs make them attractive for single particle 
detection in electron microscopy, thereby providing greater spatial resolution. Additionally, 
they provide a large surface area which behaves as a scaffold, enabling attachment of multiple 
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moieties. This tailoring of the monolayers formed on AuNPs mean that they are suitable for 
many different applications. 
 
AuNPs can be functionalised as optical probes via the addition of fluorophores, thus enabling 
introduction of multiple fluorophores to a single probe. This will result in an increase in the 
fluorescent signal for an individual probe and, as such, facilitate single molecule imaging. 
This has been achieved with a variety of fluorescent molecules including organic and 
inorganic dyes (Hong et al., 2006, Goutayer et al., 2010, Evans et al., 2010, Wang et al., 2010, 
Lewis et al., 2006, Hallett et al., 2009, Dasary et al., 2008). Functionalisation of nanoparticles 
usually arises as a result of gold-sulphur bond formation (Chung et al., 2012, Zhong et al., 
1999, Jaccob et al., 2012). 
 
Furthermore, as optical probes, gold and silver nanoparticles are known to scatter coloured 
light when illuminated with white light. An increase in diameter from 40 nm results in a 
change in colour from green to red and are easily distinguishable in cells (Yguerabide and 
Yguerabide, 1998). AuNPs with smaller diameters of around 13 nm have potential for 
scattering light at around 600 nm (Kah et al., 2008). This enables imaging of cells treated with 
AuNPs using confocal reflectance microscopy using a standard 633 nm laser. 
 
Nanoparticles have been shown to enter a variety of cells on a timescale of 2 – 24 hours of 
incubation usually via endocytosis or use of surfactants (Bickford et al., 2010, Chung et al., 
2008, Li et al., 2010, Wang et al., 2009). Of particular interest, one study reported silver 
nanoparticles entered platelets within two hours of incubation (Chung et al., 2008). However, 
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other research suggests that gold nanoparticles may cause platelet aggregation (Wiwanitkit et 
al., 2009). 
 
The delivery of gold nanoparticles in to cells without in a very short time scale ~<1 hour 
would be a big improvement on the current uptake times. Conjugation to pHLIP will enable 
this fast uptake, thereby allowing imaging of platelet and nanoparticles dynamics. In fixed 
cells the presence of the gold nanoparticles provide a probe when imaging with electron 
microscopy, and when coated with fluorophores such as a luminescent lanthanide complex 
that can bind to AuNP via the formation of a gold-sulphur bond, enable fluorescence 
microscopy in real-time. 
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1.8 THESIS AIMS 
The overall aim of this thesis is to investigate the delivery of imaging labels into human 
platelets in order to further the understanding of the role of the actin nodule in platelets. This 
can be divided into the following objectives: 
 
1. Investigate the role of the actin nodule in Lifeact-GFP mouse platelets. 
2. Examine the suitability of pHLIP as a molecular delivery agent for human platelets. 
3. Develop pHLIP as a delivery vector, in human platelets, to deliver a range of labels 
including, Lifeact peptide and gold nanoparticles. Thus facilitating live cell imaging of 
human platelet actin dynamics. 
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CHAPTER 2 
MATERIALS & METHODS 
 
2.1 REAGENTS 
Fluorescently-conjugated antibodies for αIIb and α2 were purchased from BD Biosciences 
(Oxford, UK). FITC rat anti-mouse CD41 (0.5 mgmL
-1
, in aqueous buffered solution 
containing ≤0.09 % sodium azide), PE rat anti-mouse CD41 (0.2 mgmL-1, in aqueous buffered 
solution containing ≤0.09 % sodium azide) and FITC mouse anti-human CD49b (0.5 mgmL-1, 
in aqueous buffered solution containing ≤0.09 % sodium azide). Antibodies were used as 
received, stored at 4 °C. 
 
pHLIP and Lifeact were prepared and Lifeact labelled by Alta Biosciences. The peptide 
sequences were: 
pHLIP: AAEQNPIYARYADWLFTPLLLLDLALLVDADEGTC(Thiopyridyl)-G 
Lifeact: CMGVADLIKKFESISKEEK 
The Lifeact peptide was labelled with carboxyfluorescein, FAM. Purity was checked by the 
supplier with high-performance liquid chromatography, HPLC, and matrix-assisted laser 
desorption/ionisation, MALDI, mass spectrometry where a peak observed at m/z 4349 is 
assigned to [M-H]
- 
for pHLIP and 2557 is assigned to [M-H]
-
 for Lifeact-FAM. 
pHLIP was dissolved in a sodium phosphate buffer (0.1 M, pH 7.0) with 75 % v/v DMSO to 
give a 10 mM stock solution and Lifeact-FAM was dissolved in a sodium phosphate buffer 
(0.1 M, pH 7.0) with 37 % v/v DMF to give a 5 mM stock solution. The peptides were stored 
at -20 ºC. 
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DyLight 550 Antibody Labelling Kit was purchased from Pierce. FM4-64FX lipophilic styryl 
dye was purchased from Invitrogen.  
 
EuL was prepared by D. J. Lewis as previously described (Davies et al., 2012). PlasmaCal 
Calibration standards for europium and gold were purchased from SCP science. 
 
N-succinimidyl 3-(2-pyridyldithio) propionate, SPDP, and Tris(2-carboxyethyl)phosphine 
hydrochloride, TCEP, was purchased from Pierce. 
 
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich. Solvents were 
purchased from Sigma-Aldrich or Fisher. Deuterated solvents were purchased from Goss 
Scientific or Sigma-Aldrich and used as received. HPLC grade solvents were used in 
photophysical studies. Water was deionised using an Elgar Option 3 water purifier.  
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2.2 METHODS 
2.2.1 Platelet preparation 
2.2.1.1 Preparation of murine platelets. 
All solutions were warmed to 37 °C prior to use. Fresh murine blood was obtained from CO2 
terminally anaesthetised mice by cardiac puncture and taken into acid-citrate-dextrose (ACD; 
100 μL 10% v∕v, 85 mM sodium citrate, 110 mM glucose, 80 mM citric acid). Modified 
Tyrode’s buffer (200 μL, 134.0 mM NaCl, 2.90 mM KCl, 0.34 mM Na2HPO4:12H2O, 12.0 
mM NaHCO3, 20.0 mM Hepes, 1.0 mM MgCl2, pH 7.3) containing glucose (5.0 mM) was 
added to the blood and the resulting suspension centrifuged for 5 minutes ( 200 x g) at room 
temperature. 700 μL was removed from the top of the suspension and centrifuged for 6 
minutes (200 x g) to obtain the yellow supernatant (platelet rich plasma - PRP). Washed 
platelets were prepared via centrifugation of PRP for 6 minutes (1000 x g) in the presence of 
PGI2 (0.1 µgmL
−1
). The pellet was resuspended in modified Tyrode’s buffer to a 
concentration of 2×10
8
 cellsmL
−1 
and allowed to rest for 30 minutes. 
 
2.2.1.2 Isolation of human platelet rich plasma 
All solutions were warmed to 37 °C prior to use. Fresh human blood was obtained into 
sodium citrate (10% v∕v) by venipuncture. Acid-citrate-dextrose (ACD, 10% v∕v; 85 mM 
sodium citrate, 110 mM glucose, 80 mM citric acid) was added to the blood and the resulting 
suspension transferred to polypropylene tubes and centrifuged for 20 minutes (200 × g) at 
room temperature. The yellow supernatant (platelet rich plasma - PRP) was collected. 
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2.2.1.3 Preparation of washed human platelets. PGI2 ( 0.1 µgmL
−1
) was added to the PRP 
and the suspension centrifuged for 10 minutes (1,000 × g). The resulting supernatant was 
removed and the pellet resuspended in modified Tyrode’s buffer (25 mL, 134.0 mM NaCl, 
2.90 mM KCl, 0.34 mM Na2HPO4:12H2O, 12.0 mM NaHCO3, 20.0 mM Hepes, 1.0 mM 
MgCl2, pH 7.4) containing glucose (5.0 mM) and ACD (3 ml). PGI2 (0.1 µgmL
-1
) was added 
and suspension was centrifuged for 10 minutes (1000 x g). The resultant supernatant was 
removed and the pellet resuspended in modified Tyrode’s buffer containing glucose and ACD 
as previous. The platelet suspension was diluted to 2×10
8
 cellsmL
−1
 and allowed to rest for 30 
minutes. 
 
2.2.1.4 Preparation of human platelets for treatment with pHLIP/  pHLIP-Lifeact/ 
pHLIP•AuNP samples.  
As described above (2.2.1.2), PRP was collected, PGI2 (0.1 µgmL
−1
) was added and the 
suspension centrifuged for 10 minutes (1,000 × g). The resulting supernatant was removed 
and the pellet resuspended in modified Tyrode’s buffer (25 mL, 134.0 mM NaCl, 2.90 mM 
KCl, 0.34 mM Na2HPO4:12H2O, 12.0 mM NaHCO3, 20.0 mM Hepes, 1.0 mM MgCl2, pH 6.5 
(or pH 7.4, as required)) containing glucose (5.0 mM) to a concentration of 2×10
8
 cellsmL
−1
 
and allowed to rest for 30 minutes. 
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2.2.2 Platelet functional assays 
2.2.2.1 Platelet spreading.  
Glass coverslips were coated with fibrinogen (100 μgmL−1 in PBS) at 4 °C overnight. 
Uncoated glass was blocked by denatured BSA (5 mgmL
−1
 in PBS, 1 hour at room 
temperature). Platelet suspensions were diluted to 2×10
7
 cellsmL
−1
 with modified Tyrode’s 
buffer (at pH 6.5 or pH 7.4, as required).  
For live cell imaging, platelets were allowed to spread on the coverslips in a live cell imaging 
chamber. The microscopes were fitted with an environment chamber and heated to 37 °C 
prior to imaging.  
For fixed cell samples, platelets were allowed to spread on the coverslips at 37 °C for 45 
minutes in a humidified chamber (37 °C, 5% CO2) prior to fixation with 10% formalin for 10 
minutes. Residual formalin was quenched with NH4Cl2 (50 mM) for 10 minutes at room 
temperature. Coverslips were washed three times with PBS and once with deionized water 
and mounted on glass slides using Hydromount and stored at 4 °C until imaged. 
 
2.2.2.2 Platelet inhibitor assays 
In separate experiments, platelet suspensions were treated with Cytochalasin D (10 µM), 
Latrunculin A (3 µM), Jasplakinolide (5 µM), Y27632 (20 µM), PP2 (10 µM), BAPTA-AM 
(10 µM), CK-666 (20 µM) for 10 min prior to spreading. Solvent control samples were 
treated with DMSO (0.1 % v/v), likewise. 
 
2.2.2.3 Antibody staining.  
Platelets were incubated with fluorescently labelled antibodies (1 % v/v) for 10 minutes prior 
to spreading.  
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2.2.2.4 Fixed cell actin staining.  
Following fixation and quenching with NH4Cl2, coverslips were washed three times with 
PBS. Triton X-100 (0.1 % in PBS) was added to cells for 5 minutes, washed with PBS and 
fluorescently labelled phalloidin (6.6 pM; in PBS containing BSA), Lifeact (5 pM; in PBS 
containing BSA) or Lifeact•AuNP (30 pM; in PBS) added. Samples were left in the dark for 
30 minutes, then washed with PBS and water and mounted as previously described. 
 
2.2.2.5  pHLIP/ pHLIP-Lifeact treatment of human platelets.  
Unless otherwise stated, Lifeact/ pHLIP/ 550-pHLIP/ pHLIP-Lifeact/ 550-pHLIP-Lifeact was 
added to platelet suspension (2 x 10
8
 cellsmL
-1
) for 40 minutes (room temperature). The 
suspension was then diluted with modified Tyrode’s buffer (at pH 6.5 or pH 7.4, as required) 
containing glucose to2 x 10
7
 cellsmL
-1 
prior to spreading. 
 
2.2.2.6 AuNP treatment of human platelets 
Unless otherwise stated, pHLIP•EuL•AuNP, pHLIP•AuNP, EuL•AuNP or citrate-stabilized 
AuNP (approximately 8,000 NPs∕cell or approximately 40,000 NPs∕cell for TEM and light 
microscopy, respectively) were added to the platelet suspension (2 x 10
8
 cellsmL
-1
 or 3.2×10
8
 
cellsmL
−1
 for light microscopy and TEM, respectively)  for 10 minutes (room temperature). 
The suspension was then diluted with modified Tyrode’s buffer (at pH 6.5 or pH 7.4, as 
required) containing glucose to2 x 10
7
 cellsmL
-1 
prior to spreading or platelet suspension 
fixed for TEM. 
 
2.2.2.7 Variable pH platelet experiment.  
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Following treatment with pHLIP/ pHLIP-Lifeact/ pHLIP•AuNP samples, modified Tyrode’s 
buffer (pH 6.5 for pH 6.5 samples or 7.4, and pH 6.5 to 7.4 and pH 7.4 samples) was added to 
cell suspension to a concentration of 1×10
8
 cellsmL
−1
 and allowed to rest for 10 minutes. PGI2 
(0.1 µgmL
−1
) was added and the suspension centrifuged for 10 minutes (1,000 × g). The 
resulting supernatant was removed and the pellet resuspended in modified Tyrode’s buffer 
(pH 6.5 for pH 6.5 samples or 7.4, and pH 6.5 to 7.4 and pH 7.4 samples) to a concentration 
of 2×10
7
 cellsmL
−1 
and allowed to rest for 20 minutes prior to spreading. 
 
2.2.2.8 Platelet leakage assay.  
Washed human platelets were loaded with Oregon-Green BAPTA-1 AM (1 μM) in the 
presence of CaCl2 (200 μM) and Apyrase (2 UmL
−1
) for 45 minutes at 37 °C. ACD (12 
μlmL−1) and PGI2 (0.1 µgmL
−1
) were added and the cells centrifuged for 20 minutes (700 × 
g). The resulting supernatant was removed and the pellet resuspended in modified Tyrode’s 
buffer (pH 6.5). pHLIP•EuL•AuNP (approximately 8;000 NPs∕cell), saponin (10 μgmL−1) or 
modified Tyrode’s buffer (pH 6.5) were added to the platelet suspension for 10 minutes at 
room temperature. The platelets were centrifuged for 20 minutes (700 × g) in the presence of 
PGI2 (0.1 µgmL
−1
) and the resulting supernatants retained. CaCl2 (50 μM final) was added to 
the supernatants and the emission of Oregon-Green BAPTA-1 AM between 510 nm and 600 
nm was recorded following excitation at 480 nm. The area under the curve was determined 
for each sample to determine fluorescence intensity. 
 
2.2.2.9 Labelling of the platelet membrane with FM4-64FX.  
Labelling of the platelet membrane with FM4-64FX lipophilic styryl dye was undertaken as 
per manufacturer’s instructions. All solutions were kept on ice and staining procedure was 
Chapter 2 – Materials & Methods 
Page | 62 
carried out on ice. Essentially, FM4-64FX (100 μg) was dissolved in water (100 μL) to give a 
stock solution of 1 mgmL
-1
 and stored at -20 °C. Washed platelets (2×10
7
 cellsmL
−1)
 were 
allowed to spread on fibrinogen (100 mgmL
−1
 in PBS) coated coverslips for 45 minutes. A 
working solution of dye (5 μgmL−) in PBS was prepared a few minutes prior to staining. 
Coverslips were removed from Tyrode’s buffer and quickly immersed in the staining solution 
for 1 minute. Platelets were then fixed with 10 % formalin for 10 minutes. Residual formalin 
was quenched with NH4Cl2 (50 mM) for 10 minutes at room temperature. Coverslips were 
washed three times with PBS and once with deionized water and mounted on glass slides 
using Hydromount and stored at 4 °C until imaged. 
 
2.2.2.10 Platelet Preparation for TEM.  
Following treatment with nanoparticles, treated or untreated platelet samples were centrifuged 
(10 minutes, 1,000 × g) in the presence of PGI2 (0.1 µgmL
-1
) and resuspended in 
gluteraldehyde (2.5% v/v, 0.5 M PBS). Samples were subsequently placed in 1% osmium 
tetroxide solution and gradually dehydrated with alcohol and propylene oxide. The platelets 
were embedded in resin and ultrathin sections (50 –– 150 nm) obtained which were mounted 
onto copper electron microscope grids (Formvar film). Samples were contrasted with uranyl 
acetate and lead citrate. 
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2.2.3 Preparation of pHLIP conjugates 
2.2.3.1 pHLIP-Lifeact conjugation.  
Lifeact-FAM (5 mM; 37 % v/v in sodium phosphate buffer, pH 7) was added in 8 equal 
aliquots to pHLIP (5 mM; 75 % v/v in sodium phosphate buffer, pH 7) to give a final ratio of 
8 parts Lifeact to 10 parts pHLIP. The conjugation reaction occurred at room temperature and 
in the dark to prevent bleaching of fluorescein. When necessary the peptide conjugate was 
diluted using ultrapure water.  
Reverse phase high performance liquid chromatography, HPLC, was used to determine 
conjugation of Lifeact-FAM to pHLIP. 
 
2.2.3.2 Labelling pHLIP with Dylight 550.  
The labelling of the N-terminus of pHLIP was achieved using Dylight Antibody labelling kit 
(Pierce), as per manufacturer’s instructions. Essentially, pHLIP (2 mg) was dissolved in 
sodium borate buffer (0.05 M in PBS, 1 mL). Borate buffer (0.67 M, 40 μL) was added to 
peptide solution (0.5 mL). The peptide solution (0.5 mL) was added to vial containing Dylight 
Reagent and vortexed gently. The reaction mixture was incubated for 60 minutes at room 
temperature protected from light. Purification resin (250 μL) was added to two spin columns 
and centrifuged for 1 minute (1000 x g) to remove storage solution. Peptide solution (250 μL) 
was added to each of the spin columns and vortexed to enable mixing of the resin and peptide 
solution prior to centrifugation for 1 minute (1000 x g). The eluents were collected and 
combined. The absorbance at 280 and 557 nm was measured using Nanodrop UV-Vis 
spectophotometer (Thermo Scientific) and the protein concentration and moles dye/mole 
protein calculated as 0.34 mM and 0.045 moles dye/mole protein, respectively (εpHLIP = 
13,940 M
-1
 cm
-1
, (Reshetnyak et al., 2006)). 
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2.2.3.3 Synthesis of citrate-stabilised gold nanoparticles, AuNP.  
Gold colloids were prepared as per Grabar et al (Grabar et al., 1995). Essentially, all 
glassware used in this preparation were initially washed with aqua regia (3:1 HCl/HNO3) and 
water and dried in an oven. Hydrogen tetrachloroaurate (0.17 g, 0.5 mM) was dissolved in 
deionised water (500 mL) and brought to the boil with vigorous stirring. Sodium citrate (0.57 
g, 1.9 mM) in water (50 mL) was then added rapidly to the vortex, initiating a slow colour 
change from yellow to burgundy. The resulting solution was kept at the boil for a further 10 
minutes. The solution was then allowed to cool to room temperature and stirring was 
continued for 15 minutes. The resulting AuNP were characterised using UV-Vis absorption 
spectroscopy and TEM to confirm the presence of approximately 13 nm spherical 
nanoparticles. 
 
2.2.3.4 Preparation and characterisation of pHLIP•EuL•AuNP.  
The preparation of pHLIP•EuL•AuNP was monitored by the changes of the shifts in the 
characteristic nanoparticle SPR band during titration of pHLIP and EuL using UV-Vis 
absorption spectroscopy. Ten aliquots of pHLIP (2 μL, 10 mM in sodium phosphate buffer 
(0.1 M) with 75% v/v DMSO) were added to citrate gold nanoparticles, AuNP (2.5 mL, 9.4 
nM in water) up to a final peptide concentration of 80 μM where no further shift of the SPR 
was observed. Subsequent titration of seven aliquots of EuL (12 μL, 10 mM in methanol) led 
to further shifts of the SPR up to a final EuL concentration of 0.33 mM. The solution was 
purified by size-exclusion chromatography on superfine Sephadex G25 and eluted with 
distilled water. The red band was collected and stored at 4 °C and the UV-Vis spectrum was 
repeated to ensure no changes on the SPR band following chromatography. The dilution 
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effect after the column was examined by UV-Vis spectroscopy and the final nanoparticle 
concentration was estimated to be 7.4 nM. This sample was used to treat the platelets. 
Excitation and emission spectra were acquired for diluted samples, as indicated, to avoid inner 
filter effects. Characteristic UV-Vis (H2O) λmax = 527 nm. TEM results indicate mono-
disperse nanoparticles of 13 nm diameter. Zeta potential (4.9 nM) = −29 (±1) mV. 
 
2.2.3.5 Preparation and characterisation of  pHLIP•AuNP.  
The shifts of the SPR band were monitored upon addition of aliquots of pHLIP (20 μL, 10 
mM in 0.1 M sodium phosphate buffer with 75% v/v DMSO) to AuNP (2.5 mL, 9.4 nM) to 
reach a final peptide concentration of 80 μM. The solution was purified by size-exclusion 
chromatography as described for pHLIP•EuL•AuNP, and a final concentration of 7.4 nM was 
used to treat the platelets. Characteristic UV-Vis (H2O) λmax = 523 nm. Zeta potential (4.9 
nM) = −21 (±1) mV. 
 
2.2.3.6 Preparation and characterisation of EuL•AuNP.  
The shifts of the SPR band were monitored upon addition of aliquots of EuL (30 μL, 10 mM 
in methanol) to AuNP in water (2.5 mL, 9.4 nM) to a final concentration of 0.12 mM. The 
suspension was purified by size-exclusion chromatography, as described for 
pHLIP•EuL•AuNP, and a final concentration of 7.4 nM was used to treat the platelets. 
Characteristic UV-Vis (H2O) λmax = 526 nm. TEM results indicate mono-disperse 
nanoparticles of 13 nm diameter. Zeta potential (4.9 nM) = −14 (±2) mV. 
 
2.2.3.7 Preparation and characterisation of Lifeact•AuNP.  
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The preparation of Lifeact•AuNP was monitored by the changes of the shifts in the 
characteristic nanoparticle SPR band during titration of Lifeact using UV-Vis absorption 
spectroscopy. Eight aliquots of Lifeact (1 μL, 5 mM in sodium phosphate buffer (0.1 M) with 
37% DMSO) were added to citrate gold nanoparticles, AuNP (2.5 mL, 9.4 nM in water) up to 
a final peptide concentration of 16 μM where no further shift of the SPR was observed. The 
solution was purified by size-exclusion chromatography on superfine Sephadex G25 and 
eluted with distilled water. The red band was collected and stored at 4 °C and the UV-Vis 
spectrum was repeated to ensure no changes on the SPR band following chromatography. The 
dilution effect after the column was examined by UV-Vis spectroscopy and the final 
nanoparticle concentration was estimated to be 6.3 nM. This sample was used to label 
platelets or for further synthetic steps. Emission spectra were acquired for diluted samples, as 
indicated, to avoid inner filter effects. Characteristic UV-Vis (H2O) λmax = 525 nm. 
 
2.2.3.8 Preparation and characterisation of SPDP-Lifeact•AuNP. The preparation of 
SPDP-Lifeact•AuNP was monitored by the changes in the nanoparticle SPR band following 
the addition of SPDP using UV-Vis absorption spectroscopy. As similarly described by 
manufacturers instructions and Lee et al, SPDP (400 μL, 3 mM in PBS with 10 % DMSO) 
was added to Lifeact•AuNP (400 μL, 30 nM in PBS) and stirred vigorously for 45 minutes at 
room temperature (Lee et al., 2009). Unconjugated SPDP was removed by repeated 
centrifugation for 30 minutes (13,000 rpm, 4 °C), supernatant removed and the nanoparticles 
re-dispersed in PBS (three times). After removal of supernatant following final washing step, 
the nanoparticles were re-dispersed in sodium borate buffer (400 μL). The UV-Vis spectrum 
was repeated to ensure no changes on the SPR band following washing. 
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2.2.3.9 Preparation and characterisation of pHLIP-Lifeact•AuNP. pHLIP-SH (16 μM, in 
sodium phosphate buffer with 37 % DMF) was added to SPDP-Lifeact•AuNP (15 nM, in 
sodium borate buffer or PBS) and incubated for 18 hours at room temperature. 
 
 
2.2.3.10 Reduction of disulphide bond on pHLIP, pHLIP-SH. The disulphide bond on the 
C-terminus of pHLIP was reduced by addition of TCEP (4.28 μL, 3.8 mM in PBS) to pHLIP 
(46 μL, 10 mM in sodium phosphate buffer (0.1 M) with 75 % DMF). The reaction was 
allowed to proceed at room temperature for 1 hour then the peptide was stored at 4 °C for 
several days before use. Prior to use pHLIP-SH was diluted with sodium phosphate buffer to a 
concentration of 5 mM. 
 
2.2.3.11 Lifeact•AuNP buffer compatibility. Lifeact•AuNP (6.3 nM in water) was 
centrifuged for 30 minutes (13,000 rpm, 4 °C). The supernatant was removed and the 
nanoparticles were re-dispersed in PBS, PBS-EDTA (100 mM sodium phosphate, 150 mM 
NaCl, 1 mM EDTA, 0.02 % w/v sodium azide, pH 7.5) or sodium borate buffer (0.1 M; 50 
mM boric acid, 20 mM sodium tetraborate, pH 7.5) to a Lifeact•AuNP concentration of 9.3 
nM. The UV-Vis spectrum was repeated to ensure no changes on the SPR band following 
buffer change. 
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2.3 INSTRUMENTATION 
2.3.1 Confocal reflection and fluorescence microscopy.  
Samples were imaged using the 488 nm laser line (Ar/ArKr laser), 543 nm and 633 nm laser 
line (He/Ne laser) on a Leica DMIRE 2 laser scanning confocal microscope with 63×, 1.4 
N/A. oil objective. Reflected light was collected at 478 – 498 nm and 623 – 643 nm for 
excitation of 488 nm and 633 nm, respectively. Fluorescence emission was collected at 500 - 
550 nm for GFP and FAM, 580 - 650 nm for PE and DyLight 550 and 645 – 850 for FM4-
64FX. Images were acquired using the Leica TSC SP2 software.  
 
2.3.2 Total internal reflection fluorescence microscopy.  
Live samples were imaged using the Olympus IX81 Inverted microscope with a 60x Plan Apo 
1.49 NA oil-immersion objective and a Hammamatsu ORCA-R2 C10600 12-bit CCD. 
Fluorescein was excited with a 491-50 Diode type laser and PE with a 561-50 DPSS type 
laser. Images were acquired using Xcellence Advanced Live Cell Imaging System 1.1.  
 
TIRF microscopy undertaken in the Machesky lab (Beatson Institute for Cancer Research, 
Glasgow) (Figure 3.15) was performed on a Nikon Eclipse TE 2000-U microscope equipped 
with a 60x and a 100x 1.45 NA Nikon TIRF oil immersion objectives. The Nikon Epi-
fluorescence condenser was replaced with a custom condenser in which laser light was 
introduced into the illumination pathway directly from the optical fibre output oriented 
parallel to the optical axis of the microscope. The light source for evanescent wave 
illumination was a 473 nm diode laser or 561 laser (Omicron), with each laser line coupled 
into the condenser separately in order to allow individual TIRF angle adjustments. The lasers 
were controlled by a DAC 2000 card or a uniblitz shutter operated by MetaMorph (Molecular 
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Devices). A green/red dual filterblock (ET-GFP/mcherry, AHF Analysentechnik, Germany) 
was used for dual colour excitation 473 and 561 excitation. A Multi-Spec dual emission 
splitter (Optical Insights, NM) with a 595nm dichroic and two bandpass filters (510-565 for 
green and 605-655nm for red) was used to separate both emissions. All imaging was 
performed with a Cascade 512F EMCCD camera (Photometrics UK).  
 
Live human platelets labelled with antibody for FITC-α2 (Figure 3.18) were imaged using the 
Nikon A1R inverted confocal/TIRF microscope with CFI Plan Apo TIRF 60x 1.49 N.A oil 
objective. The excitation used was, Exciter S490/20x with Dichroic 86100bs and the emission 
was collected using Emitter S528/38m for FITC. Images were acquired using NIS Elements 
AR Software Advanced Research. 
 
2.3.3 Transmission electron microscopy.  
Samples were imaged using Jeol 1200EX TEM with an operating voltage of 80 keV and 
Gatan multiscan camera. Images were acquired using DigitalMicrograph 1.8 (Gatan, CA, 
USA). 
 
2.3.4 Luminescence microscopy and spectroscopy.  
Samples were imaged using an Olympus IX71 inverted fluorescent microscope with a 
LUCPLFLN 40×, 0.60 N/A: objective coupled to an Edinburgh Instruments FLS920 
spectrophotometer. Excitation at 340 nm was achieved by a 450 W Xe lamp and EuL 
emission (>510 nm) was detected by a Hamamatsu EMCCD C9100-13. Excitation and 
emission wavelengths were controlled using Edinburgh Instruments v6.8 PC software. Images 
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were acquired using Cell^M 3.2 (Olympus Soft Imaging Solutions GmBH). Emission spectra 
were acquired using Edinburgh Instruments F900 v6.8 PC software.  
 
Steady-state luminescence experiments were carried out using an Edinburgh instruments 
FLS900 system equipped with a 450 W Xenon lamp, double excitation and emission 
monochromators. Detection of emitted photons was achieved by the use of a cooled 
Hamamatsu R928 (Vis-red sensitive) photomultiplier tube. Emission lifetimes were recorded 
on the same system using an Edinburgh Instruments μF microsecond flashlamp (1–1000 Hz) 
as excitation source and using the multichannel scaling, MCS, single photon counting 
method. Detector saturation was avoided in all circumstances by using minimal signal rate 
intensities combined with extended data collection times. Lifetime data were fitted to - decays 
using Edinburgh Instruments F900 PC software using the exponential tail fit option. 
Instrument response for lifetime data collected using the IX-71 microscope was measured 
using erythrosine in water.  
 
2.3.5 UV-Vis absorption spectroscopy.  
UV-Vis absorption spectra were recorded using a Varian Cary 5000 dual beam spectrometer.  
 
2.3.6 Inductively Coupled Plasma Optical Emission Spectroscopy, ICP-OES.  
ICP-OES analysis was run at the University of Warwick using a Perkin-Elmer 5300DV ICP-
OES system. Concentrations of europium and gold in nanoparticle samples were determined 
using linear calibration curves constructed from purchased standards, with R
2
 > 0.999 in all 
cases. 
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2.3.7 Zeta-potential measurements.  
Zeta potentials were acquired using a Beckman-Coulter DelsaNano C instrument. All samples 
studied were at 4.9 nM concentration of particles. 
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2.4 ANALYSIS OF RESULTS 
2.4.1 Analysis of live cell mouse platelet images 
Individual platelets which were observed to settle and start spreading during imaging were 
cropped to enable visualisation and analysis of platelet actin nodule dynamics. 
 
2.4.2 Analysis of number of nodules per platelet 
The number of nodules per platelet was counted for each time frame and recorded. 
Additionally, the number of frames that each individual nodule was present in was counted 
and multiplied by the time between frames to give a value for the nodule lifetime in the cell. 
 
2.4.3 Platelet area/ nodule size. 
 The mean platelet surface area or mean nodule size (μm2) of individual platelets or nodules 
was quantified using ImageJ software. 
 
2.4.4 Analysis of nodule displacement 
The coordinates of the approximate centre of nodules was recorded for each individual nodule 
at each time point. The displacement at each time point was calculated from the difference 
between the first recorded coordinates and the coordinate at the time point of interest. 
 
2.4.5 Statistics.  
Where applicable, results are shown as ± standard error mean, s.e.m. Statistical significance 
of differences between means was ascertained by Student’s t-test or one-way analysis of 
variance, ANOVA, as indicated, using GraphPad Prism v4.03 for Windows (GraphPad 
Software, San Diego California, USA, www.graphpad.com). If means were determined to be 
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significantly different with ANOVA, further multiple comparisons were undertaken using a 
Tukey test. For all results, probability values of P < 0.05 were considered to be statistically 
significant 
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CHAPTER 3 
IMAGING OF LIFEACT-GFP MOUSE PLATELETS TO ELUCIDATE THE ROLE 
OF ACTIN NODULES IN PLATELET ADHESION AND SPREADING 
 
3.1 INTRODUCTION 
Actin nodules were first described by Calaminus et al as a novel actin-rich structure in 
platelets which appear prior to lamellipodia and stress fibre formation during platelet 
spreading (Figure 3.1) (Calaminus et al., 2008). The nodules were also labelled with 
antibodies for various actin regulatory proteins, including Rac, Fyn, cortactin, talin, Arp2/3 
complex, β1- and β3-integrin subunits, and under flow and shear stress conditions, with 
activated Src (Calaminus et al., 2008, Kasirer-Friede et al., 2010). From these findings, it has 
been conjectured that the nodules may have a role in driving formation of the later forming 
actin structures, such as lamellipodia and stress fibres, while also involved in surface 
anchoring in shear stress conditions. 
 
However, this work was done using fixed human platelets stained with phalloidin or mouse 
platelets expressing actin-GFP, neither of which are suitable methods for imaging actin 
nodule dynamics. Firstly, phalloidin can only be used in fixed platelets due to its inability to 
permeate the cell membrane and the stabilising effect that phalloidin has on actin filaments 
(Wulf et al., 1979). Although, incredibly useful for imaging actin in fixed cells, fixed cells 
imaging does not provide temporal information about the nodule’s appearance, disappearance 
or what it does in between. Thus live-cell imaging is a far more useful approach to 
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understanding what an actin nodule is and its role in platelet spreading. Secondly, although 
cells expressing actin-GFP enable live cell imaging, the actin fusion proteins have been 
shown to alter the actin dynamics (Feng et al., 2005, Deibler et al., 2011). 
 
 
 
A mouse model expressing Lifeact-GFP has been developed (Riedl et al., 2010). Lifeact, an 
actin binding protein, has been shown to bind transiently with F-actin and, as such, it does not 
appear to interfere with actin dynamics to the same extent as actin-GFP (Riedl et al., 2008, 
Deibler et al., 2011). Furthermore, in a conditionally-inducible Lifeact-GFP mouse model, 
platelets appear unaffected by the presence of Lifeact-GFP and spread normally (Schachtner 
et al., 2012). Therefore, use of platelets from Lifeact-GFP mice will enable live cell imaging 
of platelet spreading and consequently the study of actin nodules. 
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It is the aim of the work in this chapter to utilise platelets from GFP-Lifeact mice to study the 
actin nodule dynamics in order to elucidate the role of the actin nodule during platelet 
spreading. 
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3.2 RESULTS & DISCUSSION 
3.2.1 Characterisation of actin nodule dynamics 
Actin nodule dynamics were first imaged using platelets from actin-GFP mice which 
suggested that these actin structures were dynamic (Calaminus et al., 2008). Live cell TIRF 
imaging of Lifeact-GFP mouse platelets confirmed the dynamic and transient nature of actin 
nodules in spreading platelets (Figure 3.2). 
 
 
 
TIRF microscopy enables imaging of the nodules at the basal cell membrane, however any 
nodules which are not present within 100 nm of the coverslip would not be seen. Therefore, to 
investigate whether there are nodules present in the platelet which are outside of the 
evanescent field, platelets were image in TIRF and epifluorescence illumination (Figure 3.3 
A). Epifluorescence microscopy enables imaging of events throughout the cell.  
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All nodules that were present in epifluorescence were also present in TIRF (Figure 3.3 B). 
Additionally, nodule appearance and disappearance occurred at the same time in both TIRF 
and epifluorescence (Figure 3.3 C). This suggests that all nodules in the cell are at the basal 
membrane and that TIRF microscopy is suitable for imaging nodule dynamics. 
 
All platelets contained actin nodules with their first appearance a matter of seconds after the 
platelet adheres to the fibrinogen surface (Figure 3.4 A-B). The number of nodules in a 
platelet rapidly increases in the first 30 seconds of spreading to an average of 5 nodules and 
thereafter the numbers remain fairly constant. Although nodule numbers remain steady, the 
individual nodules continually turn-over, with nodules displaying a range of lifetimes from 3 
seconds to greater than 150 seconds. On average the nodule lifetime is 31.2 (± 1.53) seconds 
with the vast majority of nodules (86 %) persistent for less than 50 seconds (Figure 3.4 C). 
The maximum observed displacement of individual actin nodules was less than 0.4 μm. This 
value is equivalent to three pixels. Given that the nodules were 2-3 pixels wide and the centre 
of the was approximated by eye it is unlikely that the nodules moved and the displacement 
due to errors in determination of the centre of nodules. Consequently, the nodules were not 
found to be mobile but instead remained in the same location, at which they first appeared, for 
their entire lifetime (Figure 3.4 D). Additionally, the fluorescent area of the nodules was 
determined which showed that it fluctuates throughout the nodule lifetime (Figure 3.4 Ei) but 
the overall trend is for the fluorescent area to increase in the first 50 % of its lifetime and then 
decrease until it disappears (Figure 3.4 Eii).  
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Nodules were localised throughout the platelet and assigned one of the following categories; 
(1) “periphery” when localised to the platelet edge, (2) “centre” when localised within the 
main body of the cell, (3) “filopodia base” when localised to the area from which a filopod 
protrudes and (4) “filopodia” when found along the filopodia structure (Figure 3.5 A). The 
majority of nodules were found to be localised to the cell periphery (Figure 3.5 B). The 
localisation of the nodules in the platelet does not appear to affect the lifetime of a nodule 
(Figure 3.5 C). 
 
The actin nodule is a dynamic actin structure which is present in all platelets within seconds 
of adhesion which suggests that the actin nodule may not have a role in initial platelet 
adhesion events. However, the nodules appear prior to the formation of the main platelet actin 
structures, filopodia, lamellipodia and stress fibres, so it may have a role in initial platelet 
spreading events. Each nodule remains stationary and persists for approximately 30 s but is 
quickly replaced by another nodule, as evidenced by the number of nodules per cell remaining 
fairly constant. The nodules are present throughout the cell volume and distributed across the 
cell. Their presence at the cell periphery and at the base of filopodia may indicate a role in 
platelet adhesion or in the formation of filopodia and lamellipodia which protrude from the 
cell periphery. 
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3.2.2 Actin polymerisation is required for nodule formation  
Previous work suggested that the actin nodule was a dynamic structure which relied on actin 
polymerisation for their formation and stability (Calaminus et al., 2008). However, this relied 
on stained, fixed platelets. Live-cell TIRF microscopy of spreading of Lifeact-GFP mouse 
platelets treated with Cytochalasin D demonstrated the inability of the platelets to spread 
properly upon a fibrinogen-coated surface, failing to produce filopodia (Figure 3.6 A).  
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However, the majority (70 %) of the rounded platelets contained at least one actin nodule 
(Figure 3.6 B) with platelets exhibiting a mean of 2 nodules/cell for >50 % of the imaging 
time (Figure 3.6 C), a decrease on the figure seen for control samples. The mean nodule 
lifetime (18.9 s ± 4.40) is significantly decreased compared with control samples and 95 % of 
nodules have a lifetime less than 50 s (Figure 3.6 D). The nodules remained immobile 
throughout their lifetime (Figure 3.6 E). 
 
 
Lifeact-GFP mouse platelets were treated with Latrunculin A, before spreading on fibrinogen 
coated coverslips and imaged live using TIRF microscopy. These platelets did not spread 
normally, instead remained rounded without the appearance of filopodia (Figure 3.7). 
Furthermore, no nodules were present in any platelets. 
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Lifeact-GFP mouse platelets were treated with Jasplakinolide, before spreading on fibrinogen 
coated coverslips and imaged live using TIRF microscopy. These platelets did not spread 
normally, instead remained rounded without the appearance of filopodia (Figure 3.8). 
Furthermore, no nodules were present in any platelets. These rounded platelets had a reduced 
contact surface area compared with other rounded platelet samples, Latrunculin A or 
Cytochalasin D. 
 
 
 
 
While addition of Latrunculin A resulted in loss of nodules, treatment with Cytochalasin D 
did not. Unexpectedly nodule turnover remained reasonably dynamic in Cytochalasin D 
treated platelets. Additionally no nodules were present in platelets treated with Jasplakinolide. 
Since Jasplakinolide is a potent inducer of actin polymerisation (Bubb et al., 1994) and 
prevents depolymerisation, it would be expected that if nodules were present in platelets prior 
to activation, they would still be present in the activated platelets. Since there are no actin 
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nodules present, the platelets may instead be filled with a disorganised soup of actin filaments 
preventing the platelet from forming the organised actin structures which enable the platelet to 
spread. Therefore, these results suggest that nodules are formed immediately upon activation 
of the platelet as a result of actin polymerisation. 
 
 
3.2.3 Actin nodule turnover correlated with ROCK activity 
Previous work by Calaminus et at showed that addition of the ROCK inhibitor, Y27632 (50 
μM), to human platelets resulted in inhibition of stress fibre formation and a doubling of the 
number of actin nodule containing platelets (80 %) compared with the DMSO control (45 %) 
(Calaminus et al., 2008). To further investigate the role of ROCK in actin nodules, live cell 
imaging of Lifeact-GFP mouse platelets treated with Y27632 (20 μM) was undertaken 
(Figure 3.9 A). This revealed that all platelets contained at least one actin nodule at some 
point during their lifetime (Figure 3.9 B-C). The number of actin nodules is increased in 
Y27632 treated platelets with cells exhibiting a mean of 6 nodules/cell for >50 % of the time 
the platelets were imaged for. However, the mean nodule lifetime was significantly decreased 
(20.2 s ± 0.79) with 95 % of nodules having a lifetime of less than 50 s (Figure 3.9 D). 
Similarly to control samples, nodules in Y27632 treated platelets were stationary (Figure 3.9 
E). 
 
These results support the previous hypothesis that ROCK is not required for actin nodule 
formation. Furthermore, the increased nodule turn over, as inferred by the decrease in nodule 
lifetimes and increase in the number of nodules per cell, suggests that ROCK may play a role  
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in the stability of the nodules. In particular, it may be that disappearance of nodules may be as 
a result of actin depolymerisation. 
 
 
3.2.4 Src family kinase activity and actin nodule dynamics  
The original work describing nodules investigated the role of Src kinase activity in human 
platelets on actin nodules using the Src kinase inhibitor, PD0173952. They found that actin 
nodules were absent in PD0173952 treated platelets and conclude that the formation and 
stability of actin nodules required continuous actin polymerisation downstream of Src kinases 
(Calaminus et al., 2008). To investigate the role of Src kinase activity on actin nodule 
dynamics, Lifeact-GFP mouse platelets were treated with another SFK inhibitor, PP2, before 
spreading on fibrinogen coated coverslips and imaged live using TIRF microscopy. These 
platelets did not spread normally, instead remained rounded without the appearance of 
filopodia (Figure 3.10 A). Also, the nodules were different in appearance to those seen for 
control samples and instead appear less well defined and fuzzy. All platelets had at least one 
nodule present per cell at some point during the experiment window (Figure 3.10 B-C). These 
nodules had a highly significant reduction in mean lifetime (8.2 s ± 0.42) compared with 
control platelets (31.2 s ± 1.53) with 100 % of nodules having a lifetime of less than 40 
seconds (Figure 3.10 D). Again, nodules were immobile (Figure 3.10 E). 
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To further investigate which of the Src family kinases (SFK) have a role in actin nodules, 
platelets from loss-of-function mouse mutants for the Src family kinases, Lyn
-/-
, Lyn
-/-
/Fyn
-/-
and Src
-/-
/Fyn
-/- 
(Severin et al., 2012) and their wild type (WT) controls were allowed to 
spread on fibrinogen coated coverslips for 45 minutes prior to fixation and staining with 
phalloidin-488. Platelets from all mouse models appeared to spread normally (Figure 3.11 A), 
however, there was a highly significant decrease in the number of spread platelets for Lyn
-/-
/Fyn
-/-
and Src
-/-
/Fyn
-/-
 (Figure 3.11 B). The percentage of nodule containing cells for Lyn
-/- 
platelets was similar to WT platelets but a significant decrease was observed for Lyn
-/-
/Fyn
-/-
and Src
-/-
/Fyn
-/-
 (Figure 3.11 C). However, in platelets that did contain actin nodules, the 
distribution of the number of nodules per cell was similar (Figure 3.11 D). 
 
 
These results support the previous hypothesis that actin nodule formation and stability 
requires Src kinase activity. Loss of Lyn, Lyn and Fyn or Src and Fyn did not appear to affect 
the number of actin nodules per platelet which suggests that other SFK’s may be involved 
instead of/ as well as Lyn, Fyn and Src in nodule formation and dynamics. 
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3.2.5 The role of calcium in actin nodule dynamics 
Changes in local concentrations of [Ca
2+
]i are implicated in the reorganisation of the actin 
cytoskeleton and subsequent platelet shape change. There are several Ca
2+
-dependent 
signalling pathways and actin regulatory proteins, such as gelsolin, which bind Ca
2+
 that are 
involved in regulation of the actin cytoskeleton (Ariyoshi and Salzman, 1996, Yin and 
Stossel, 1979, Furukawa et al., 2003). Additionally, a rise in [Ca
2+
]i is observed at the point 
from which filopodia and lamellipodia form, suggesting a role for Ca
2+
 in regulating their 
formation (Ariyoshi and Salzman, 1996, Hartwig, 1992). 
 
Live-cell TIRF microscopy of spreading of Lifeact-GFP mouse platelets treated with 
BAPTA-AM demonstrated the inability of the platelets to spread properly upon a fibrinogen-
coated surface (Figure 3.12 A). Platelets remained mostly rounded with only one or two 
abnormally long filopodia formed. The majority of cells (85 %) produced at least one actin 
nodule during the experiment window (Figure 3.12 B). Furthermore the time from cell 
attachment to nodule appearance (~36 s) was noticeably longer than for control samples (3 s). 
Platelets exhibited a mean of 2 nodules/cell for >50 % of the imaging time, representing a 50 
% decrease on the figure seen for control samples (Figure 3.12 C). These nodules have a 
similar mean lifetime of 24.2 s (± 1.73) to the control platelets, with 91% of nodules having a 
lifetime less than 50 s (Figure 3.12 D). Nodule position remained constant throughout nodule 
lifetime (Figure 3.12 E). 
 
 
The abnormally long filopodia have been previously observed in platelets treated with Quin-2, 
which suggested that calcium has a role in cytoskeletal reorganisation (Hartwig, 1992). The  
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decrease in the number of nodules per platelet when incubated with the Ca
2+
 chelating agent, 
BAPTA-AM, suggests that Ca
2+
 may also play a role in the cytoskeletal reorganisation 
required for actin nodule formation. 
 
 
3.2.6 The role of Arp2/3 complex in actin nodule dynamics 
Actin nodules have previously been reported to co-localise with Arp2/3 complex in 
immunohistochemistry studies (Calaminus et al., 2008). To further investigate the role of 
Arp2/3 in actin nodule formation and dynamics, live cell imaging of Lifeact-GFP mouse 
platelets treated with CK-666 (20 μM) was undertaken (Figure 3.13). These platelets did not 
spread normally, instead remained rounded without the appearance of filopodia. Furthermore, 
no nodules were present in any platelets. The complete lack of nodules upon inhibition of 
Arp2/3 suggests that it is required for actin nodule formation in platelets. 
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3.2.7 Spatial and temporal relationship between actin nodule formation and filopodia 
emergence 
As apparent from Figure 3.5, a quarter of nodules in a platelet are localised to the base of a 
filopodia structure. This together with the nodule being the first actin structure apparent in 
spreading platelets suggests that there may be a relationship between nodule formation and 
filopodia formation. The following section of work investigates if there is such a relationship. 
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Nodules which localised to the filopodia base were tracked and the temporal relationship 
between the nodule appearance and filopodia appearance was determined (Figure 3.14 A). 86 
% of nodules appeared before or concurrently with filopodia emergence (Figure 2.14 B). 63 % 
of nodules appeared less than 9 seconds before filopodia appearance which is early in the 
lifetime of an average actin nodule (Figure 3.14 C). 
 
Since filopodia formation occurs both before and after actin nodule appearance it is unlikely 
that the actin nodule is required for filopodia formation. This is further supported by the 
observation that not all filopodia have an actin nodule at their base. However, the prevalence 
of actin nodule appearance at the base of filopodia suggests there may be a relationship 
between actin nodules and filopodia dynamics. 
 
 
3.2.8 Spatial and temporal relationship between actin nodules and platelet surface 
receptors 
Among the actin regulatory proteins found to co-localise with actin nodules were the β1- and 
β3-integrin subunits (Calaminus et al., 2008). The co-localisation of these integrin subunits 
insinuates a role in actin nodule dynamics. The two most abundant platelet integrins each 
contain one of the β subunits, the fibrinogen receptor, αIIbβ3, and the collagen receptor, α2β1. 
Since both fibrinogen and collagen play a role in platelet spreading, investigating the 
dynamics of their respective integrins in relation to the actin nodule will further enhance our 
understanding of the function of actin nodules in platelets. 
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Relationship between actin nodules and the fibrinogen receptor, αIIbβ3 integrin 
Work undertaken during a visit to the Machesky lab (Beatson Institute for Cancer Research, 
Glasgow) utilised their Lifeact-RFP mouse model to preliminarily assess the TIRF 
microscopy potential of platelets from a Lifeact mouse model. Platelets were also labelled 
with FITC-conjugated antibody for the αIIb-integrin subunit to examine the possibility of 
live-cell dual-labelling studies. The punctate pattern of integrin labelling appeared to co-
localise with the actin nodules (Figure 3.15). Pearson’s correlation analysis was performed to  
 
 
 
gauge the degree of correlation between the actin staining and integrin labelling. The 
correlation coefficient, r, was 0.83 (± 0.05) which indicates a high degree of co-localisation 
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since r = 1 represents perfectly co-localised imaged and r = -1 represents mutually exclusive 
images (Bolte and Cordelières, 2006, Purbhoo et al., 2010). 
 
 
Having ascertained the viability of live-cell dual-labelling TIRF microscopy studies for 
Lifeact mouse platelets and established a potential relationship between nodules and the 
integrin, further work was undertaken using platelets from Lifeact-GFP mice. This work aims 
to study the nature of the interactions and dynamics of the actin nodule and the αIIb-integrin 
subunit using a PE-conjugated antibody for αIIb. 
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Rapid, sequential, two-colour, real-time TIRF microscopy of GFP-Lifeact platelets labelled 
with a PE-conjugated antibody for αIIb enabled imaging of the relationship between actin 
nodule dynamics and αIIb integrin (Figure 3.16). It may be possible that the interaction with 
the antibody and αIIb-integrin subunit may inhibit the interaction of αIIb with fibrinogen. 
However, platelets appeared to spread normally, with nodule numbers and turnovers similar 
to untreated platelets, suggesting that at this concentration, the interaction with the antibody 
and αIIb-integrin subunit does not affect platelet spreading or nodule formation. All actin 
nodules co-localised with αIIb-rich structures (Figure 3.17 A). The majority of the actin 
nodules (> 75 %) appeared and disappeared concurrently with αIIb integrin cluster 
appearance. When broken down by cellular localisation of nodules and their associated 
integrin clusters, there was a decrease in the percentage of nodules which appeared 
concurrently with the integrin clusters for nodules which were localised to the centre of the 
cells (Figure 3.17 B). Although the integrin clusters mostly disappeared at the same time as 
the actin nodule disappearance, an integrin cluster did not always remain associated with an 
actin nodule (Figure 3.17 C). Instead for approximately 20 % of nodules the initial integrin 
cluster, disappeared and a second integrin cluster associated with the actin nodules. This 
turnover of the integrin-rich structures occurred more frequently for nodules at the base of 
filopodia (Figure 3.17 D). Additionally, these integrin-rich structures were only present when 
co-localised with actin nodules. 
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Relationship between actin nodules and the collagen receptor, α2β1 integrin 
Although α2β1 is the most abundant collagen receptor on the platelet surface, there are only 
approximately 2000 copies per cell (Clemetson and Clemetson, 2001, Best et al., 2003). 
αIIbβ3 has far more copies per cell, in the region of 50,000 – 80,000 (Wagner et al., 1996). 
This difference in copies per cell would result in a decrease in the number of fluorescently 
labelled antibodies bound to the cell and consequently a decrease in the fluorescent signal. 
Therefore to test whether it is possible to image the integrin dynamics on platelets, human 
platelets were incubated with a fluorescently conjugated antibody for α2 prior to spreading on 
collagen coated coverslips. Platelet spreading was monitored in real time using TIRF 
microscopy (Figure 3.18). 
 
 
 
Unlike with αIIb labelling, the whole cell is not visible. Instead discrete clusters of 
fluorescence are visible as the platelet adheres to the surface. The number of clusters increase 
as the platelet spreads. These results demonstrate that it is possible to image α2 integrin 
dynamics on the platelet surface. 
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Unfortunately, it was not possible to image actin dynamics of Lifeact-GFP mouse platelet 
spreading on a collagen surface using TIRF microscopy due to the unevenness of the collagen 
surface. The uneven surface meant that not all of the platelet was visible within the 
evanescent field. However based on previous observations that actin nodules co-localised 
with β1, it may be that those α2-rich integrin clusters localised to actin nodules and two-
colour TIRF studies similar to that used for αIIb are needed to determine if this is the case. 
 
The co-localisation of actin nodules with αIIb throughout the nodule lifetime and the position 
of all nodules near the basement membrane (See 3.2.1) suggest that nodules may be involved 
in adhesion. Other adhesion actin structures such as podosomes and focal adhesions both 
contain integrins enabling linking of the cytoskeleton to the ECM (Block et al., 2008). 
Previous work has found that actin nodules also co-localise with talin, vinculin and paxillin 
which are present in both focal adhesions and podosomes (Calaminus et al., 2008, Barnes, 
2011). However, it is unlikely that the nodules represent either structure because they differ 
structurally from podosomes, for instance, no inner core of actin and they do not form rosette 
structures, and unlike focal adhesions they do not co-localise with pFAK and disappear prior 
to stress fibre formation (Calaminus et al., 2008, Barnes, 2011). Instead the actin nodule may 
represent a different adhesion structure in platelets. 
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3.3 CONCLUSIONS 
Live-cell TIRF microscopy of Lifeact-GFP mouse platelets has enabled further research of the 
role of actin nodules in platelet spreading (Figure 3.19). The actin nodule is a transient actin 
rich structure which forms within seconds of platelet adhesion to matrix proteins. The actin 
nodules are localised to the basal membrane, throughout the platelet, and remain stationary 
during their lifetime which is on average 31 s. Actin nodule formation requires actin 
polymerisation downstream of SFK activity and the presence of Arp2/3 complex, while 
ROCK appears to play a role in nodule stability. Additionally actin nodule formation and 
disappearance are associated with formation and disappearance of αIIb-rich structures which 
co-localise with the actin nodule. 
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The stationary nature of the actin nodule, its localisation to the basal membrane and its co-
localisation with actin associated proteins which are present in podosomes and focal 
adhesions, suggest that the actin nodules may play a role in platelet adhesion. Their 
disappearance prior to formation of stress fibres suggest that their involvement is in initial 
adhesion events but not necessarily in stable adhesion. Therefore, the actin nodule may 
represent a novel adhesion structure in platelets. 
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CHAPTER 4 
DELIVERY OF THE ACTIN BINDING PROTEIN, LIFEACT, INTO HUMAN 
PLATELETS USING pH (LOW) INSERTION PEPTIDE 
 
4.1 INTRODUCTION 
Reliable visualisation of the actin cytoskeleton is essential for further understanding of 
platelet actin dynamics, in particular, the actin nodule. In order to do this fluorescently 
labelled actin or actin binding proteins are required to label the actin. The discovery of GFP 
and its analogues and their incorporation into fusion proteins which can be expressed in other 
organisms, enabled the generation of GFP-actin fusion proteins (Shimomura et al., 1962, 
Tsien, 1998, Era et al., 2009, Yoon et al., 2002). Previously, this had mostly been achieved 
via injection of fluorescently labelled actin or addition of fluorescently labelled phalloidin. 
However, all of these methods have their drawbacks, including; phalloidin’s cytotoxicity and 
GFP-actin fusions impair actin function (Cooper, 1987, Feng et al., 2005). This led to the 
exploration of actin binding domains as GFP fusion protein labels. 
 
Due to the high sensitivity of platelet membranes and their lack of a nucleus, fluorescent label 
injection and cell transfection are not viable for use with human platelets. As a result, staining 
of fixed cells with fluorescently labelled phalloidin is the most prevalent technique for human 
platelets (Thomas et al., 2007, Calaminus et al., 2008, Mori et al., 2012). However, the use of 
fluorescently labelled actin binding domains, in particular Lifeact, has potential as an actin 
label in live human platelets (Riedl et al., 2008). Lifeact is derived from the first 17 amino 
acids of ABP140 in Saccharomyces cerevisiae. Its small size and its lower affinity for actin 
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than phalloidin (actin-phalloidin; 30 pM and actin-Lifeact; 1.3 μM), means that it does not 
appear to affect actin polymerisation or depolymerisation (Riedl et al., 2008, Deibler et al., 
2011, Wulf et al., 1979, Faulstich et al., 1977). This has proved useful for looking at actin 
dynamics in platelets (Chapter 3) and their precursor megakaryocyte cells in GFP-Lifeact 
mouse models (Schachtner et al., 2012, Schachtner et al., 2013). However, Lifeact has mostly 
been used as a transgenicly expressed protein in cells or have been introduced via ‘scrape 
loading’, neither are suitable for human platelets (Riedl et al., 2008, Riedl et al., 2010, Munsie 
et al., 2009, Bottcher et al., 2009, Lizarraga et al., 2009, Li et al., 2008). 
 
 
 
Instead, this work introduces the use of pH (low) insertion peptide, pHLIP, to facilitate the 
delivery of Lifeact into human platelets. A 38 amino acid peptide, pHLIP has delivered a 
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variety of cell impermeable compounds, including phalloidin, into the cytoplasm of cells 
when conjugated via a disulphide bond to the peptide’s C-terminus (Reshetnyak et al., 2006, 
An et al., 2010, Reshetnyak et al., 2011). The mechanism for pHLIP’s cytoplasmic delivery of 
cargo is pH-dependent (Figure 4.1). Essentially; at neutral pH, pHLIP exists as an 
unstructured monomer and loosely associates with the lipid membrane (State I-II). Upon a 
reduction in pH to 6.5 or lower, pHLIP forms an α-helix and spontaneously inserts itself, C-
terminus first across the lipid membrane (State III) (Karabadzhak et al., 2012). Thereby, 
translocating any cargo molecules bound to its C-terminus across the lipid membrane. The 
reducing environment of the cell cleaves the disulphide bond between pHLIP and its cargo, 
thereby releasing it into the cell (An et al., 2010, Wijesinghe et al., 2011, Moshnikova et al., 
2013). Increasing the pH back to neutral results in the removal of pHLIP from its 
transmebrane situation (Andreev et al., 2010). 
 
 
The work in this chapter aims to explore the suitability of Lifeact as an actin label and pHLIP 
as a delivery vector in human platelets. Fluorescently labelled Lifeact is conjugated to 
pHLIP’s C-terminus via a disulphide bond, thereby releasing the translocated Lifeact peptide 
into the cytoplasm to label F-actin. Consequently, delivery of Lifeact into live cells will 
enable live cell imaging of actin dynamics in human platelets and facilitate research into the 
dynamics of the platelet actin nodule. 
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4.2 RESULTS & DISCUSSION 
4.2.1 Lifeact as an actin label in human platelets 
Lifeact peptide was synthesised following the sequence described by Riedl et al (Riedl et al., 
2008) but with the addition of two extra amino acids; a cysteine residue was added to the N-
terminus to enable conjugation to pHLIP via a disulphide bond and an additional lysine added 
to the C-terminus to enable addition of a fluorescent label. For this work Lifeact was labelled 
with carboxyfluorescein, FAM. Lifeact was dissolved in DMF (37 % v/v in sodium phosphate 
buffer (0.1 M, pH 7.0)). 
 
Spread and fixed human platelets were permeablised and stained with 488-phalloidin or 
Lifeact-FAM (Figure 4.2). Comparable labelling of actin structures, including nodules, 
filopodia, lamellipodia and stress fibres, by phalloidin and a range of Lifeact concentrations is 
apparent in various representative stages of platelet spreading. The transient nature and 
relatively low F-actin affinity of Lifeact does not appear to affect actin labelling as evidenced 
by comparable actin labelling by Lifeact at various concentrations and that of phalloidin. 
However, the Lifeact labelled actin appears “fuzzier” than actin labelled with phalloidin, this 
may be as a result of the transient binding nature of Lifeact to actin, resulting in the presence 
of both actin bound and unbound label (Riedl et al., 2008, Riedl, 2011). 
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In spread, fixed and permeablised cells 6.6 pM Lifeact is sufficient to label the platelet actin 
cytoskeleton. However, in non-permeablised cells molecules are not able to enter the cells as 
easily, if at all, so increasing the concentration of Lifeact in cell solution would increase the 
likelihood of uptake, if Lifeact is able to permeate the membrane. Human platelets were 
incubated with Lifeact-FAM for 40 minutes in various pH conditions prior to spreading on 
fibrinogen and fixation (Figure 4.3) to assess whether Lifeact-FAM is able to enter non-
permeablised platelets on its own. Although, there was some labelling, it was very faint and 
may be due to fixation related membrane permeability. 
 
 
 
 
Lifeact peptide is able to label actin in permeablised platelets and appears to be unable to 
permeate the cell membrane on its own. Therefore, fluorescently labelled Lifeact is an ideal 
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candidate for cellular delivery using pHLIP in order to label the actin cytoskeleton of live 
human platelets. 
 
 
 
4.2.2 pHLIP as a delivery agent for human platelets 
The C-terminal of pHLIP, when inserted into a lipid membrane, is found in the cytoplasm of 
the cell and, as such, is the target for cargo molecule conjugation. In order to achieve this 
pHLIP was synthesised as per the sequence described by Reshetnyak et al but with the 
addition of a thiopyridyl group added to the C-terminus cysteine residue (Reshetnyak et al., 
2006). The presence of the thiopyridyl group prevents disulphide bonds forming between 
cysteine residues of other pHLIP molecules and it also enables disulphide exchange with a 
cysteine residue of the cargo molecule. Consequently, allowing efficient conjugation of 
pHLIP to a cargo molecule such as Lifeact. pHLIP was dissolved in DMSO (75 % v/v in 
sodium phosphate buffer (0.1 M, pH 7.0)). 
 
The effect of pHLIP on platelets in suspension was investigated. Following treatment of 
platelets with various concentrations of pHLIP at pH 6.5 for 10 minutes the number of 
platelets in the suspension was counted (Figure 4.5). At 10 μM pHLIP there was a highly 
significant decrease in the platelet number relative to 0.0 μM pHLIP control sample but not 
for any other concentration. This suggests that at pHLIP concentrations of 10 μM or more 
pHLIP affects cell viability. Therefore, pHLIP will be used at concentrations less than 10 μM. 
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Following the protocol used by An et al., for calculating amount of phalloidin that needs to be 
delivered, using pHLIP, per cell when treating HeLa cells (An et al., 2010), human platelets 
were incubated with pHLIP (6.6 µM), under various pH conditions, for 40 minutes prior to 
spreading on fibrinogen and fixation. The platelets were then imaged using confocal reflection 
microscopy to assess platelet spreading (Figure 4.5 A). There was no significant difference in 
the mean cell density of spread platelets, mean platelet area or in the distribution of platelets 
at various spreading stages for platelets in any pH conditions when compared with their 
respective solvent control samples (Figure 4.5 B-D). Therefore, incubation with pHLIP at 6.6 
µM does not appear to affect platelet spreading. 
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The N-terminal of pHLIP was labelled with a DyLight 550 fluorescent label to enable 
visualisation of pHLIP on/in the platelet membrane. Dye to peptide ratio was calculated to be 
0.04 moles of DyLight 550 per mole of pHLIP, indicating a labelling efficiency of 4 %. The 
final peptide concentration was determined to be 0.34 mM. 
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pHLIP labelled with DyLight 550, 550-pHLIP, was added to human platelets at various pH 
conditions for 40 minutes prior to spreading on fibrinogen and fixation. The platelets were 
then imaged using confocal reflection and fluorescence microscopy (Figure 4.6). The majority 
of cells treated with 550-pHLIP exhibited fluorescence regardless of the pH conditions during 
treatment (Figure 4.7 A). However, the cellular localisation of this fluorescence differed with 
pH (Figure 4.7 B). All labelled cells had pronounced labelling in the centre of the cell, while 
for platelets treated at pH 7.4 the majority of cells (92 %) displayed only central labelling, the 
entire of the cell surface was labelled for the majority of platelets (89 %) treated at pH 6.5. 
Platelets treated at pH 6.5 but then the pH increased to pH 7.4, were evenly split between the 
proportion of cells entirely labelled (44 %) and only labelled in the cell centre (56 %). 
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In all pH conditions there was a large concentration of pHLIP in the central region of the 
platelet. Since pHLIP binds to/inserts across the cell membrane, 550-pHLIP is a membrane 
label so the greater concentration in the centre of platelets could be as a result of increased 
membrane area from the open canalicular system. To assess whether this was the case 
platelets were labelled with FM4-64FX lipophilic styryl dye to label the platelet membrane 
(Figure 4.8). The fluorescence signal from the dye was very weak; however the membrane 
dye shows an increased concentration in the centre of the platelets, while the rest of the 
platelet surface is also labelled. The increased concentration in the centre of cells is similar to 
that of 550-pHLIP at pH 6.5. This suggests that the greater labelling of the cell centre may be 
due to increased membrane surface area. 
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Addition of pHLIP to platelets in various pH conditions and at the various concentrations 
tested does not appear to affect platelet spreading on fibrinogen, thus demonstrating the 
potential suitability of pHLIP for use as a delivery agent in human platelets. The labelling of 
pHLIP with 550 DyLight enabled visualisation of the distribution of pHLIP on the platelet. 
The difference in the fluorescence pattern between platelets treated at pH 6.5 and at pH 7.4 
corresponds well with the model for pHLIP properties; at pH 7.4, pHLIP is loosely bound to 
the membrane so it is expected that less pHLIP would be associated with the membrane than 
at pH 6.5. When the platelets were treated at pH 6.5 and then the pH increased to 7.4, there 
was a reduction in the amount of entirely labelled cells corresponding with the removal of 
pHLIP from the membrane. 
 
 
4.2.3 Conjugation and characterisation of pHLIP-Lifeact 
Conjugation of pHLIP to Lifeact via formation of a disulphide bond between cysteine residue 
of Lifeact and cysteine-thiopyridyl of pHLIP will result in the release of pyridine 2-thione, 
P2T, (Figure 4.9). P2T produces an absorbance at around 343 nm (Zhao et al., 2002). So 
assaying for the presence of P2T using UV-Vis absorbance spectroscopy would be an 
indicator of conjugation of Lifeact to pHLIP. However, this assay was unsuccessful due to the 
very low concentration of P2T produced which was not detectable. 
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Instead, reverse phase HPLC was utilised to determine whether conjugation occurred. Lifeact-
FAM eluted at 21.6 minutes, pHLIP at 27.4 minutes and there was a third absorbance peak 
that eluted at 25.9 minutes that following MS analysis proved to be pHLIP-Lifeact (Figure 
4.10 A). Although quantification of how much pHLIP-Lifeact was formed is not possible 
from this HPLC technique, the optimum conjugation conditions were determined via 
monitoring of the increases/ decreases in the area of the absorbance peak for each of the three 
peptides (Figure 4.10 B). The actual percentages are not important or useful in this situation 
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due to differences in the absorbance of 215 nm light by each peptide. However, for each 
peptide after addition of 6 parts Lifeact-FAM to 10 parts pHLIP, the values plateaued 
suggesting that no further conjugation occurred. Therefore, to ensure maximum amount of 
conjugation eight times 1 part Lifeact-FAM was added to 10 parts pHLIP. 
 
 
 
 
4.2.4 Treatment of human platelets with pHLIP-Lifeact 
Human platelets were incubated with pHLIP-Lifeact (6.6 µM) in various pH conditions for 40 
minutes. The pH was either kept constant or increased to pH 7.4 to remove excess, 
untranslocated pHLIP-Lifeact prior to spreading on fibrinogen (Figure 4.11). Platelets 
incubated with pHLIP-Lifeact at pH 7.4 displayed faint membrane labelling, if any, but there 
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is labelling in the centre of the cell, as was previously noticed for 550-pHLIP treated platelets. 
When platelets were treated at pH 6.5, labelling of the actin cytoskeleton is apparent. In 
samples where the pH was increased to remove excess or untranslocated pHLIP-Lifeact from 
the platelet membrane, there is a reduction in the amount of labelling as indicated by the 
decreased fluorescence intensity (Figure 4.15 F) but there is still clear actin labelling. In both 
samples, labelling of the central platelet region was present. 
 
 
 
In order to assess the uptake, release and actin labelling of Lifeact delivered using pHLIP, 
Lifeact-FAM was also conjugated to the fluorescently labelled pHLIP analogue, 550-pHLIP. 
This conjugation enables visualisation of both pHLIP and Lifeact and their subsequent 
interactions with human platelets using fluorescence microscopy. Due to the importance of 
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the pH in dictating uptake, human platelets were incubated with 550-pHLIP-Lifeact in a 
variety of pH conditions. 
 
 
 
Human platelets treated with 550-pHLIP-Lifeact at pH 7.4 exhibited fluorescence from both 
550-Dylight and Lifeact-FAM (Figure 4.12). The fluorescent patterns of both labels were 
similar and showed only patterns of membrane labelling. As previously observed with 550-
pHLIP only, labelling was concentrated in the central platelet region. The similar membrane 
labelling pattern suggests that pHLIP and Lifeact are still conjugated. It is expected that this is 
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due to pHLIP only being associated with the platelet membrane at neutral pH and as such that 
Lifeact has not been delivered to the cytoplasm. 
 
 
 
Human platelets treated with 550-pHLIP-Lifeact at pH 6.5 exhibited fluorescence from both 
550-Dylight and Lifeact-FAM (Figure 4.13). The fluorescent patterns of both labels were 
distinct, with 550-pHLIP exhibiting membrane labelling and the platelet actin cytoskeleton 
labelled with Lifeact-FAM. However, a similar pattern of labelling was seen for both 
fluorophores in the cell centre. This could be due to pHLIP-Lifeact remaining conjugated 
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within this region. The evident difference in surface labelling with pHlIP and actin labelling 
with Lifeact, is indicative that Lifeact-FAM has been translocated across the cell membrane 
by pHLIP and then the disulphide bond cleaved between the two peptides, enabling release of 
Lifeact into the cytoplasm. 
 
 
 
Human platelets were incubated with 550-pHLIP-Lifeact at pH 6.5 and then the pH increased 
to 7.4 (Figure 4.14). The treated platelets exhibited fluorescence from both 550-Dylight and 
Lifeact-FAM. Similar to labelling at pH 6.5, the fluorescent patterns of both labels were 
Chapter 4 – Delivery of Lifeact into human platelets using pHLIP 
Page | 124 
distinct, with 550-pHLIP exhibiting membrane labelling and the platelet actin cytoskeleton 
labelled with Lifeact-FAM. However, membrane labelling with 550-pHLIP was reduced 
while Lifeact-FAM actin labelling appeared unaffected. Thus demonstrating that restoration 
of neutral pH is able to remove pHLIP from the platelet membrane. Additionally, if any 
Lifeact-FAM was still bound to pHLIP this would also be removed therefore reducing 
background fluorescence. 
 
The central labelling was not reduced following the pH increase suggesting that pHLIP in this 
region may be protected from the pH change. Such protection could arise as a result of 550-
pHLIP-Lifeact residing in vesicles. 
 
Similarly to incubation with pHLIP only, there was no significant difference in the mean cell 
density of spread platelets, mean platelet area or in the distribution of platelets at various 
spreading stages for platelets in any pH conditions when compared with their respective 
solvent control samples (Figure 4.15 A-C). All platelets exhibited fluorescence from Lifeact-
FAM at all pH conditions (Figure 4.15 D) but the location of that labelling differed (Figure 
4.15 E). For all pH conditions, there was labelling of the central region of platelets, as was 
previously observed for 550-pHLIP only platelet incubation. There was a highly significant 
decrease in the percentage of platelets with actin labelling for platelets treated at pH 7.4 (6.3 ± 
6.2) when compared with those treated at pH 6.5 (71.7 ± 4.4) or varied pH (68.0 ± 6.9). 
Conversely, the percentage of platelets exhibiting membrane labelling at pH 7.4 (75.7 ± 9.2) 
was highly significantly greater than at pH 6.5 (23.9 ± 3.2) or varied pH (26.1 ± 5.3). There 
was a highly significant decrease in the mean fluorescence intensity for platelets treated at pH 
6.5 (71.3 ± 1.8) and those at varied pH (39.7 ± 1.6), although, both were highly significantly 
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greater than at pH 7.4 (27.7 ± 1.8) (Figure 4.15 F). Since there was no significant difference 
in the percentage of platelets with actin labelling, the decrease in fluorescence intensity must 
be as a result of removal of untranslocated pHLIP-Lifeact from the platelet membrane upon 
increasing the pH. 
 
Similarly to results of platelets incubated with pHLIP only, incubation of human platelets 
with pHLIP-Lifeact at 6.6 μM does not appear to affect platelet spreading in any of the pH 
conditions. 70% of human platelets exhibit actin staining indicating  uptake of Lifeact-FAM 
into the platelets when incubated at pH 6.5 is comparable with the 78 % of HeLa cells 
labelled with dansyl observed by Reshetnyak et al at pH 6.5 (Reshetnyak et al., 2006). 
Additionally, the difference between the percentage of platelets with actin or membrane 
labelling at the different pH conditions corresponds well with the model for pHLIP properties; 
at pH 7.4, pHLIP is loosely bound to the membrane so it is expected that less pHLIP would be 
associated with the membrane than at pH 6.5.  The results demonstrate that uptake of Lifeact 
is pH dependent and, therefore, was delivered by pHLIP. 
 
 
4.2.5 Effect of pHLIP/ pHLIP-Lifeact on human platelets 
The effect of the different experimental pH conditions on platelet spreading was examined 
(Figure 4.16). There was no significant difference in the mean cell density of spread platelets, 
mean platelet area nor in the distribution of platelets at various spreading stages for platelets 
treated at pH 6.5 or pH 6.5 and increased to pH 7.4 compared with platelets treated at the 
normal pH of 7.4. Therefore, the pH conditions required for pHLIP to deliver cargo 
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molecules, pH 6.5 or pH 6.5 increased to pH 7.4 following treatment, do not appear to affect 
platelet spreading. 
 
 
 
Overall, spreading of human platelets on fibrinogen was unaffected by the pH conditions used 
or incubation with pHLIP or pHLIP-Lifeact (Table 43.1). There was no significant difference 
in the mean cell density, the mean platelet area or the distribution of platelets at various 
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spreading stages. These results suggest that low pH mediated delivery of Lifeact into platelets 
using pHLIP may be a suitable alternative for phalloidin labelling in permeablised cells. 
 
 
 
 
It is particularly important for live-cell imaging to remove any excess fluorophore in solution 
in order to reduce background noise and improve cell clarity. In order to remove excess or 
untranslocated pHLIP-Lifeact from the platelet suspension, the platelets were centrifuged 
following treatment (Figure 4.17). Prior to spreading, the platelet count was determined for 
platelets before and after washing for platelets treated at a variety of pHLIP concentrations  
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(Figure 4.17 A). There was no significant difference in platelet count between the unwashed/ 
washed samples for each pHLIP concentration. However, once spread, fixed and imaged, 
there appeared to be a reduction in the number of spread cells for pHLIP treated and washed 
platelets (Figure 4.17 B). It was found that there was a highly significant decrease in the cell 
density for pHLIP-treated and washed platelets (18.1 ± 1.7) when compared with washed 
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control platelets (30.3 ± 2.1). However, there was no significant difference between the 
unwashed (35.9 ± 2.8) and the washed (30.3 ± 2.1) control platelets. 
 
 
4.2.6 Live cell imaging of human platelets treated with pHLIP-Lifeact 
 
 
 
Attempts at live cell, real-time confocal fluorescence and reflection microscopy of human 
platelets treated with pHLIP-Lifeact were unsuccessful (Figure 4.18). Although, some 
labelled platelets were observed, they were not observed during the spreading process so no 
real time information can be drawn from them. This was mostly due to restraints of the 
imaging system which include: Laser scanning is slow, so a smaller area needs to be imaged 
therefore reducing the probability of imaging a spreading platelet. The computer memory was 
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not sufficient to enable longer time imaging of the platelets which would have increased the 
probability of imaging platelets spreading in the field of view. 
 
 
 
 
Although, successful labelling and imaging of human platelets was observed using TIRF there 
were a few issues: Limited numbers of platelets spread in the imaging field of view, possibly 
due to local heating effects caused by the laser illumination. There is high background 
fluorescence resulting from excess pHLIP-Lifeact in the cell solution which affects the image 
clarity. Additionally, the bright labelling of the central region of the platelet greatly affects the 
ability to image these cells using TIRF. The first two issues could be resolved by increasing 
the number of platelets added to the imaging chamber and by washing the treated platelets via 
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centrifugation. However, as previously noted (Figure 4.17), centrifugation of pHLIP treated 
platelets resulted in dramatic loss of platelet numbers. 
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4.3 CONCLUSIONS 
This work has demonstrated that the fluorescently labelled Lifeact peptide is a suitable actin 
label for human platelets. Furthermore, it has been shown that the addition of a cysteine 
residue to the N-terminus of Lifeact enables conjugation of Lifeact to pHLIP via a disulphide 
bond. This then enables rapid cellular uptake and release of Lifeact into human platelets, a 
cell which has proven difficult to deliver non-permeant molecules into while the cell is 
unfixed. Consequently, this enables imaging of the actin cytoskeleton in non-permeablised 
cells. 
 
Incubation of human platelets with 550-pHLIP-Lifeact in various pH conditions demonstrates 
several important aspects about the pHLIP-Lifeact method (Figure 4.20). Firstly, at all pH 
conditions some pHLIP is associated with the platelet membrane. Secondly, when the pH is 
lowered, the membrane labelling is increased, tallying with the increased membrane affinity 
of pHLIP in low pH conditions. Thirdly, only in low pH conditions is actin labelling 
discernible, inferring both the successful translocation of Lifeact across the lipid membrane 
and its cleavage from pHLIP once in the cytoplasm. Finally, increasing the pH back to neutral 
allows for removal of excess or untranslocated pHLIP-Lifeact from the platelet membrane. 
 
Incubation of human platelets with pHLIP or pHLIP-Lifeact did not appear to affect platelet 
spreading on fibrinogen for the most part. However, the presence of pHLIP does appear to 
affect the numbers of platelets able to spread following incubation with pHLIP and 
centrifugation. 
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Most importantly, the delivery of Lifeact into platelets using pHLIP has permitted real-time, 
live-cell microscopy of actin dynamics in human platelets. This represents a significant step 
forward in the ability to image actin dynamics in human platelets and can provide a stepping 
stone to further the research of human platelet actin dynamics. Additionally, this method 
allows for delivery of other fluorescent labels to image the dynamics of other intracellular 
platelet proteins. 
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CHAPTER 5 
DELIVERY OF LUMINESCENT EUROPIUM COATED GOLD NANOPARTICLES 
INTO HUMAN PLATELETS USING pH (LOW) INSERTION PEPTIDE 
 
A publication arose from the work presented in this chapter; 
Davies, A., Lewis, D. J., Watson, S. P., Thomas, S. G. & Pikramenou, Z. 2012. pH-controlled 
delivery of luminescent europium coated nanoparticles into platelets. Proceedings of the 
National Academy of Sciences, 109, 1862-1867. 
 
5.1 INTRODUCTION 
Gold nanoparticles are attractive for use in biological and biomedical applications due to their 
optical properties and low cellular toxicity (Ghosh et al., 2010). Their tuneable size and high 
electron density make them attractive for single particle detection, thereby providing greater 
spatial resolution. Additionally they provide a scaffold upon which multiple moieties may be 
attached in order to further tailor the nanoparticle properties for specific purposes. The 
cellular uptake of a great variety of nanoparticles has been investigated, including quantum 
dots (Popovic et al., 2010, Liu et al., 2008, Smith et al., 2008, Derfus et al., 2004, Gao et al., 
2004, Akerman et al., 2002) and cell-penetrating peptide coated nanoparticles (Saha et al., 
2011, Nativo et al., 2008). However, many of these rely on endocytic mechanisms of cellular 
uptake or cell permeablisation through use of surfactants, none of which are suitable for use 
with platelets. 
 
Methods that allow delivery of optical probes to nonpermeabilized cells, with no loss of 
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cellular function, will facilitate the application of dynamic live cell imaging which is essential 
for continual advancement in understanding the molecular mechanisms governing cell 
activation and cell function. These molecular mechanisms are of particular importance in 
platelets as they play a critical role in thrombosis and haemostasis. Platelets express a range of 
surface receptors and signalling peptides, as such, are very sensitive to external stimuli. This 
sensitivity allows for fulfilment of platelet function via fast platelet activation, aggregation 
and clot formation following vessel wall damage, thereby restraining blood loss (Nieswandt 
and Watson, 2003). While an advantage for platelet function, this sensitivity is a disadvantage 
for ex vivo platelet imaging studies which require delivery of optical labels, preventing 
delivery via permeablisation or microinjection. Furthermore, the anucleate state of platelets 
prohibits transfection. As a result, live cell studies are limited to transgenic mouse models 
expressing GFP-fusion proteins (Riedl et al., 2010, Okabe et al., 1997, Schachtner et al., 
2012). Such models are time consuming to produce (Lin, 2008) and are not always suitable 
substitutes for human cells. 
 
To facilitate cellular uptake of nanoparticle labels to enable live cell imaging of platelets, this 
work introduces the addition of pH (low) insertion peptide, pHLIP, to luminescent gold 
nanoparticles. pHLIP, a 38 amino acid peptide, has been shown to insert itself, C-terminus 
first, across the plasma membrane upon a reduction in pH from neutral to pH <6.5, thereby 
translocating any cargo molecule attached to the C-terminus across the cell membrane 
(Reshetnyak et al., 2006). pHLIP has been shown to deliver a variety of cell impermeable 
compounds including phalloidin and fluorescent molecules, such as Cy5 (An et al., 2010, 
Reshetnyak et al., 2011). Its ability to deliver fluorescently labelled Lifeact peptide in to 
human platelets was also demonstrated in Chapter 4. Furthermore, attachment of pHLIP to 5 
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nm gold nanoparticles via the peptide’s N-terminus to enable detection of tumour cells has 
been previously investigated (Yao, 2008, Yao et al., 2012). The insertion of pHLIP occurs 
when the aspartic acid residues are protonated upon a reduction in pH, resulting in the 
peptide, which is loosely associated with the lipid membrane, undergoing a conformational 
change enabling it to insert itself across the lipid membrane (Reshetnyak et al., 2008). 
 
In order to optically detect the pHLIP-coated AuNP, the nanoparticles will also be coated with 
a luminescent lanthanide label since the lanthanide’s unique properties are fitting for 
biological imaging. Such properties include distinctive emission profiles in visible and near 
infrared spectral regions, large stokes shifts and long luminescence lifetimes (Bunzli, 2010, 
Montgomery et al., 2009, Moore et al., 2009). The Pikramenou group has previously 
demonstrated functionalisation of gold nanoparticles with a europium containing lanthanide 
complex (Lewis et al., 2006) and investigated their effect on cells (Lewis et al., 2010).  
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Although successful coating was achieved, quenching of the luminescence by the gold 
resonance was observed (Lewis et al., 2006). To avoid this quenching of the europium 
luminescence, a complex was designed based on a DTPA-bisamide ligand with a quinoline 
sensitiser group and surface-active (sulphur containing) groups with ‘long legs’ (Figure 5.1) 
(Davies et al., 2012). The advantages of using such a europium complex, EuL, are the 
neutrality of the complex, its stability (Paulroth and Raymond, 1995), and, unlike the free 
Eu
3+
 ion, it does not interact with peptide moieties on the nanoparticle surface (Savage and 
Pikramenou, 2011). 
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The work in this chapter presents a method which enables controlled and rapid cytosolic 
delivery of luminescent nanoparticles into human platelets. The gold nanoparticles are coated 
with both a delivery peptide, pHLIP, and a luminescent lanthanide complex, EuL to achieve 
pH-dependent delivery of pHLIP•EuL•AuNP (Figure 5.2). The attachment of pHLIP to AuNP 
via its C-terminus results in the translocation of pHLIP across the lipid membrane and into the 
cytoplasm. It demonstrates, that luminescent gold nanoparticles are delivered into the 
cytoplasm of human platelets using a variety of microscopy techniques and this uptake is due 
to the low pH induced, conformational change of pHLIP from stage I to III. These results 
were further verified via comparisons with pHLIP-coated AuNP, pHLIP•AuNP, and EuL-
coated AuNP, EuL•AuNP. 
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5.2 RESULTS & DISCUSSION 
5.2.1 Preparation and characterisation of gold nanoparticle samples 
Citrate-stabilised gold nanoparticles 
Citrate-stabilised gold nanoparticles were synthesised according to Grabar et al (Grabar et al., 
1995). UV-Vis absorbance spectroscopy was used to determine the characteristic absorbance 
maximum of the surface plasmon resonance (SPR) band at 518 nm (Figure 5.3 A). 
Transmission electron microscopy (TEM) of the citrate-stabilised AuNP showed mono-
dispersed, spherical particles of 13 – 15 nm (Figure 5.3 B). Citrate AuNP were found to have 
a zeta (ζ-) potential of -38 (±5) mV as a result of the negatively charged citrate molecules 
(Table 5.1). 
 
 
 
 
Europium-coated gold nanoparticles, EuL•AuNP. 
A solution of a red luminescent probe, designed for attachment to nanoparticle surfaces 
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(Davies et al., 2012), EuL (10 mM, in methanol) was titrated into the aqueous suspension of 
citrate-stabilised AuNP (9.4 nM, in water). This led to an 8 nm red shift in the nanoparticle 
SPR band confirming the binding of EuL to AuNP via the dithiol anchor points (Figure 5.4 
A). This shift in the SPR band was concentration-dependent and the levelling off of the SPR 
peak increase is indicative of fully coating AuNP with EuL. The EuL-coated AuNP, 
EuL•AuNP, were purified by size-exclusion chromatography to remove any excess, unbound 
EuL. Following chromatography, the λmax of the SPR band did not shift confirming the 
unchanged nature of the nanoparticle coating. A solution of EuL•AuNP exhibited the 
characteristic f-f europium luminescence spectrum upon excitation of the quinoline absorption 
band at 340 nm (Figure 5.4 B). An excitation spectrum of EuL•AuNP, monitored at the 
strongest emission band at 614 nm, demonstrated that energy transfer from the quinoline 
chromophore to the lanthanide centre is responsible for the population of the Eu
3+
 luminescent 
state (
5
D0). The luminescence lifetime of 287 μs was observed for europium in EuL•AuNP. 
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Inductively coupled plasma optical emission spectrometry, ICP-OES, was used to determine 
gold to europium ratio of 80 Au: 1 Eu for EuL•AuNP. Previous work in the Pikramenou 
group estimates the number of gold atoms per 13 nm AuNP as 106,800 (Lewis et al., 2006). 
Since there are 80 times fewer Eu present as Au then there are 80 times fewer Eu than Au 
present per AuNP than there are Au per AuNP. As such, the number of EuL complexes per 
AuNP is approximated to be 1,335 (Table 5.1). Furthermore, EuL•AuNP were found to have a 
ζ-potential of -14 (±2) mV indicative of replacement of negatively charge citrates with the 
neutral EuL molecules. 
 
 
pHLIP-coated gold nanoparticles, pHLIP•AuNP 
A solution of pHLIP (10 mM in 0.1 M sodium phosphate buffer with 75% DMSO) was 
titrated into an aqueous suspension of citrate-stabilised AuNP (9.4 nM, in water) (Figure 5.5). 
The red shift in the SPR band confirms the binding of pHLIP to AuNP. The titration was 
continued until a maximum shift of 5 nm in the AuNP SPR band was observed. This 
maximum shift is indicative of fully coating of AuNP with pHLIP. The interaction of pHLIP 
with AuNP is expected to take place via the disulfide linkage of the peptide in the C-terminus 
area. This is envisaged to be the strongest affinity site for gold (Levy et al., 2004, Nativo et 
al., 2008, Lewis et al., 2006) and any electrostatic interaction is excluded due to the negative 
charge on both nanoparticles and peptide (Guo and Gai, 2010).  
 
The pHLIP-coated AuNP, pHLIP•AuNP, were purified by size-exclusion chromatography to 
remove any excess, unbound pHLIP. Following chromatography, the λmax of the SPR band 
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did not shift confirming the unchanged nature of the nanoparticle coating. Additionally, 
pHLIP•AuNP were found to have a ζ-potential of -21 (±1) mV consistent with replacement of 
the negatively charged citrate molecules with pHLIP (Table 5.1).  
 
 
 
 
pHLIP- and EuL-coated gold nanoparticles, pHLIP•EuL•AuNP  
A solution of pHLIP (10 mM in 0.1 M sodium phosphate buffer with 75% DMSO) was 
titrated into an aqueous suspension of citrate-stabilised AuNP (9.4 nM, in water) (Figure 5.6 
A). The titration was continued until a maximum shift of 5 nm in the AuNP SPR band was 
observed, similar to that recorded for pHLIP•AuNP (Figure 5.5). This maximum shift is 
indicative of fully coating of AuNP with pHLIP. The red shift in the SPR band confirms the 
binding of pHLIP to AuNP. Subsequently, a solution of EuL (10 mM, in methanol) was 
titrated in to the pHLIP-coated AuNP suspension which led to a further 4 nm shift in the SPR 
band confirming the binding of EuL to AuNP (Figure 5.6 A). The pHLIP and EuL-coated 
AuNP, pHLIP•EuL•AuNP, were purified by size-exclusion chromatography to remove any 
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excess, unbound pHLIP and EuL. Following chromatography, the λmax of the SPR band did 
not shift confirming the unchanged nature of the nanoparticle coating.  
 
 
 
Similarly to EuL•AuNP, an emission spectrum was acquired for pHLIP•EuL•AuNP which 
also exhibited the characteristic f-f europium luminescence when excited at 340 nm (Figure 
5.6 B). The luminescence lifetime was calculated to be 290 μs, in accord with 287 μs 
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observed for EuL•AuNP. TEM images showed revealed spherical, mono-disperse 
nanoparticles with a diameter of 13 - 15 nm (Figure 5.6 C). 
 
Furthermore, ICP-OES was used to determine the gold to europium ratio in 
pHLIP•EuL•AuNP, as previously described for EuL•AuNP. The ratio was found to be 
approximately 167 Au: 1 Eu which equates to an estimated 640 EuL complexes per AuNP 
(Table 5.1). The decrease in ζ-potential from -37 mV for citrate AuNP to -29 (±1) mV for 
pHLIP•EuL•AuNP is indicative of replacement of the negatively charged citrate molecules 
with pHLIP and EuL. 
 
 
Table 5.1 summarises the main properties of the citrate AuNP and various coated AuNP. The 
shift in the SPR band upon addition of either pHLIP or EuL is indicative of their binding to 
the nanoparticle surface. The values in the table are the maximum shifts that were achieved 
suggesting the nanoparticles were fully coated with pHLIP or EuL. However, upon titration of 
EuL into a solution of fully coated pHLIP•AuNP, a further red shift was achieved. The λmax 
for pHLIP•EuL•AuNP was greater than that for either EuL•AuNP or pHLIP•AuNP indicting 
that the addition of EuL did not displace pHLIP from the nanoparticle surface. This result was 
further supported by the ICP-OES result where pHLIP•EuL•AuNP had around half the 
amount of EuL per AuNP than fully coated EuL•AuNP, 640 and 1,335, respectively. ζ-
potential measurements showed that the ζ-potential for pHLIP•EuL•AuNP was an 
intermediate value (-29 mV) between neutrally coated EuL•AuNP (-14 mV) and entirely 
negative coatings of citrate AuNP (-38 mV). Similarly, the differences in the ζ-potentials for 
pHLIP•EuL•AuNP and pHLIP•AuNP, confirm the differences in coating. These results and 
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the similar Eu
3+
 luminescent lifetimes for pHLIP•EuL•AuNP and pHLIP•AuNP confirm the 
different coatings of the nanoparticles. 
 
 
 
 
5.2.2 Uptake of gold nanoparticles into human platelets 
As optical probes, gold nanoparticles are known to scatter coloured light when illuminated 
with white light (Yguerabide and Yguerabide, 1998).The side-scatter spectra of the various 
gold nanoparticles demonstrated this scattering through a range of wavelengths from 400 – 
700 nm (Figure 5.7). In particular, strong scattering of light between 450 - 500 nm and 600 - 
700 nm was observed. A biological imaging technique which makes use of scattered light is 
confocal reflection microscopy. The stronger scattering regions of the gold nanoparticles 
coincide with conventional microscope laser lines of 488 nm and 633 nm and since scattering 
of light by biological tissues is minimal compared to that of the gold nanoparticles (Kah et al., 
2008, Curtis, 1964), making the technique ideal for monitoring gold nanoparticle uptake into 
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cells. 
 
 
 
Spread platelets were imaged using confocal reflection microscopy with incident light of λ = 
488 or 633 nm and collection of reflected light (λ ± 5 nm). Platelets treated with 
pHLIP•AuNP or pHLIP•EuL•AuNP had high regions of reflection from the gold observed as 
white spots (Figure 5.8), confirming the presence of nanoparticles in the cells. Untreated 
platelets and platelets treated with EuL•AuNP did not display these bright regions, indicating 
the absence of nanoparticles in the cells. 
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The nanoparticles can also be detected via luminescence microscopy due to the presence of 
EuL on the AuNP. Platelets were treated with EuL•AuNP, pHLIP•AuNP or 
pHLIP•EuL•AuNP for 10 minutes prior to spreading on fibrinogen and fixation (Figure 5.9). 
The spread platelets treated with pHLIP•EuL•AuNP exhibited luminescence when imaged 
with 340 nm excitation wavelength. The large separation between the excitation and emission 
wavelengths, 340 nm and >510 nm, respectively, removes any background cellular 
autofluorescence, as such the emission detected can only come from the europium. Untreated 
wavelengths, 340 nm and >510 nm, respectively, removes any background cellular 
autofluorescence, as such the emission detected can only come from the europium. Untreated 
cells and cells treated with EuL•AuNP or pHLIP•AuNP did not exhibit any luminescence, 
confirming the lack of background autofluorescence and demonstrating no uptake of 
europium-coated nanoparticles in the absence of pHLIP. In addition, transmitted light images 
of platelets treated with pHLIP•AuNP or pHLIP•EuL•AuNP have bright regions near the 
platelet centre which were not apparent in untreated platelets or platelets treated with 
EuL•AuNP. These bright regions are similar to those seen in confocal reflection microscopy 
which indicates that it may be as a result of light scattered from the gold nanoparticles in the 
platelets. 
 
Furthermore, luminescence spectrum acquired from pHLIP•EuL•AuNP treated platelets 
(Figure 5.10) showed the characteristic f-f transition pattern observed for europium, 
confirming the europium as the source of the emitted light. The luminescence lifetime for EuL 
was also examined to assess the environment of EuL inside the cell. The platelets treated with 
pHLIP•EuL•AuNP displayed a luminescence lifetime of 288 μs in spread platelet samples and 
277 μs in fixed platelet suspension in buffer, in agreement with the solution of 
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pHLIP•EuL•AuNP as reported above. The luminescence lifetime of the Eu signal confirms 
that the EuL is attached to the nanoparticle and that its coordination environment has not 
changed. Taken together, these results confirm the presence of pHLIP•EuL•AuNP in the cells. 
 
 
 
 
The high electron density of gold makes it a useful label in electron microscopy. In order to 
determine the localisation of the nanoparticles in the platelets, platelets were either untreated 
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or treated with EuL•AuNP, pHLIP•AuNP or pHLIP•EuL•AuNP for 10 minutes prior to 
fixation and preparation for transmission electron microscopy, TEM (Figure 5.11). 
Nanoparticles were mostly visible in membranous regions of the platelet including the 
internal sides of the platelet membrane, membranes of the open canalicular system and 
vesicles in platelets treated with pHLIP-coated gold nanoparticles. A small number of 
nanoparticles were also present in the platelet cytoplasm. Furthermore, no nanoparticles were 
detected in platelets treated with EuL•AuNP.  
 
Platelets treated with EuL•AuNP, pHLIP•AuNP or pHLIP•EuL•AuNP showed loss of the 
discoid structure when compared with untreated samples. Since this shape change is apparent 
in EuL•AuNP treated platelets, where no nanoparticles were detected in the platelet 
cytoplasm, this suggests that the presence of coated gold nanoparticles in platelet suspension 
may be causing slight activation of platelets. 
 
 
Cell membranes are negatively charged and ζ-potential measurements for the various 
nanoparticle samples were also negative (Table 5.1). Previous work has demonstrated that 
nanoparticle uptake is charge dependent, with nanoparticles with positive ζ-potentials taken 
up more efficiently than those with negative ζ-potentials (Arvizo et al., 2010, Liang et al., 
2010). pHLIP-coated nanoparticles have more negative ζ-potentials than EuL•AuNP, so if 
uptake was reliant on the nanoparticle/ membrane charge interaction, it would be expected 
that EuL•AuNP would be taken up into cells more efficiently. Since, this was not the case the 
results suggest that cellular uptake of pHLIP-coated nanoparticles was not due to their surface 
charge. 
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pHLIP attachment to AuNP is via a gold-sulphur bond which not easily cleavable and 
intracellular sulphur exchange reactions with glutathione are very slow (Hong et al., 2006). 
As such, when the nanoparticle is translocated across the cell membrane the nanoparticle 
should remain at the internal cell membrane. The localisation of pHLIP to membranous 
regions of the cell, such as membranes of OCS and cell membrane, was shown by TEM 
(Figure 5.11). Since the nanoparticles are localised to membranes, if the pH of the cell 
solution was increased to pH 7.4 this should result in removal of the nanoparticles from the 
inside of the cell (Figure 5.12 A). 
 
Platelets were treated, as previously described (5.2.2), after 10 minutes incubation with 
pHLIP•EuL•AuNP the pH was either increased to pH 7.4 or kept at pH 6.5 for a further 10 
minutes prior to spreading on fibrinogen, as previous. As a further control platelets were also 
treated with pHLIP•EuL•AuNP at pH 7.4. In cells treated at pH 7.4 or at pH 6.5 and increased 
to pH 7.4, there are very small regions of high reflection compared with those cells treated at 
pH 6.5 only (Figure 5.12 B). 
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5.2.3 Effect of nanoparticle uptake on platelets 
Translocation of 13 nm gold nanoparticles across the cell membrane could result in disruption 
of the platelet membrane or create holes in membrane. Either of these would cause loss of 
cellular contents. In platelets, loss of cellular contents occurs when platelets are activated and 
causes an activation signalling cascade; therefore if the nanoparticles punch holes in the cell 
membrane then this would affect platelet spreading.  
 
In order to assess whether nanoparticle uptake affects membrane integrity, human platelets 
were loaded with the cell permeant calcium indicator, Oregon-Green BAPTA-1AM prior to 
treatment with pHLIP•EuL•AuNP. As a control platelet samples were also left untreated and 
treated with saponin, a membrane pore-forming compound. Calcium was then added to the 
resulting supernatant from the centrifuged platelet samples and emission spectra acquired 
(Figure 5.13). The results show that treatment with saponin resulted in loss of BAPTA from 
the cells into the supernatant, however, this was not the case for untreated or 
pHLIP•EuL•AuNP treated cells suggesting that uptake of  the nanoparticles does not cause 
disruption to the cell membrane such that loss of cell content occurs. 
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There was no significant difference in the mean cell density of spread platelets, mean platelet 
area or in the distribution of platelets at various spreading stages for platelets in incubated with 
pHLIP•EuL•AuNP samples when compared with solvent control samples (Figure 5.15 A-C). 
Although there was a significant difference in mean cell density for pHLIP•AuNP treated 
platelets (41.4 ± 3.6) compared with solvent control (28.0 ± 3.6), there was no significant 
difference in the mean platelet area or in the distribution of platelets at various spreading stages. 
Therefore, incubation with pHLIP-coated AuNP and translocation of nanoparticles by pHLIP 
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into platelets does not appear to affect platelet spreading. 
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5.3 CONCLUSIONS 
This work has demonstrated that 13 nm gold nanoparticles can be functionalised with pHLIP 
or with a luminescent europium complex. Furthermore, it has been shown that it is possible to 
functionalise gold nanoparticles with multiple entities, in the case of this work, a peptide 
which facilitates non-endocytic uptake of nanoparticles into cells and a luminescent complex 
which enables detection of the nanoparticles in the cells. This functionalisation allows for the 
rapid uptake of luminescent gold nanoparticles into human platelets, a cell type which is 
notoriously difficult to deliver non-permeant molecules into.  
 
Due to the intrinsic properties of pHLIP, uptake into human platelets is pH-dependent and 
only achievable at a pH of <6.5. This thereby enables not only the ability to deliver 
nanoparticles non-endocytically but also provides a degree of control over the nanoparticle 
uptake. The uptake of pHLIP-coated gold nanoparticles into platelets was verified by confocal 
reflection microscopy, luminescence microscopy and transmission electron microscopy. As 
hypothesised (Figure 5.1), due the intrinsic properties of pHLIP and the nature of the 
attachment of pHLIP to AuNP, translocated nanoparticles were localised to membranous 
regions of the platelet. The presence of these luminescent nanoparticles in platelets did not 
appear to affect membrane integrity and platelets were able to spread on fibrinogen as normal. 
Thus, the introduction of pHLIP together with lanthanide label on gold nanoparticles 
represents a significant step forward in the use of gold nanoparticles as multi-modal imaging 
labels in biological systems. 
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CHAPTER 6 
DELIVERY OF FLUORESCENT LIFEACT COATED GOLD NANOPARTICLES 
INTO HUMAN PLATELETS USING pH (LOW) INSERTION PEPTIDE 
 
6.1 INTRODUCTION 
In the work presented in Chapter 5, successful coating of 13 nm gold nanoparticles with 
pHLIP and a luminescent label, EuL, was demonstrated (Davies et al., 2012). These 
nanoparticles were also successfully translocated across the plasma membrane, into the 
platelet cytoplasm, by pHLIP. However, the luminescent gold nanoparticles remained 
localised to membranous regions because there is no cleavable bond between pHLIP and the 
luminescent nanoparticles. Additionally, the luminescent nanoparticles are non-specific 
labels, so are unable to bind to and label the actin cytoskeleton or any other cellular structure 
if released into the cytoplasm. 
 
There are various approaches that could be used to enable release of AuNP into the 
cytoplasm, including glutathione-mediated release, photo-cleavage, peptide cleavage or 
disulphide bond cleavage. Glutathione-mediated release of molecules bound to gold 
nanoparticles has been achieved but it is a slow process, occurring over 96 hours or 8 hours if 
cellular glutathione concentrations are increased (Han et al., 2005, Hong et al., 2006). Photo-
cleavage or peptide cleavage has not been reported, to date, for pHLIP mediated delivery. 
Release of molecules from pHLIP following peptide insertion and cargo translocation has 
been achieved via the presence of a disulphide bond between pHLIP and the cargo molecule 
(Reshetnyak et al., 2006, Moshnikova et al., 2013, Wijesinghe et al., 2011, An et al., 2010). 
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The disulphide bond is cleaved in the reducing environment of the cytoplasm. In Chapter 4, 
this approach was used to successfully release Lifeact into the platelet cytoplasm and enabled 
imaging of the platelet actin cytoskeleton. Therefore, a disulphide bond between pHLIP and 
AuNP should enable cytoplasmic release of AuNP. 
 
However, the difficulty with achieving this goal arises from the adsorption of disulphides onto 
the gold nanoparticle surface and subsequent formation of gold-sulphur bonds and cleavage of 
sulphur-sulphur bonds. One such way that has been used to achieve disulphides on AuNPs is 
to conjugate a linker to a fully coated AuNP (Lee et al., 2009). 
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The work in this chapter aims to address both the issue of AuNP cytoplasmic release and 
AuNP label specificity via the introduction of Lifeact-FAM to AuNP, Lifeact•AuNP, with a 
disulphide bond between pHLIP and Lifeact, pHLIP-S-S-Lifeact•AuNP (Figure 6.1). The 
presence of Lifeact-FAM on AuNP enables binding to and consequently labelling of the actin 
cytoskeleton once the nanoparticles have been delivered and released into the cytoplasm. Use 
of pHLIP-S-S-Lifeact•AuNP in platelets would enable imaging of the actin cytoskeleton with 
high spatial and temporal resolution: The presence of fluorescently labelled Lifeact allows for 
live cell imaging of platelet actin dynamics, providing temporal resolution. Following which 
the same platelets can be fixed and prepared for electron microscopy, providing high spatial 
resolution of the actin in the same cells. The ability to do this would enable greater 
understanding of platelet actin dynamics and more particularly that of the platelet actin 
nodule. 
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6.2  RESULTS &DISCUSSION 
6.2.1 Preparation and characterisation of Lifeact-coated gold nanoparticles 
Citrate-stabilised gold nanoparticles 
Citrate stabilised gold nanoparticles were synthesised as previously described in Chapter 5. 
See 5.2.1 “Citrate-stabilised gold nanoparticles” for details. 
 
Lifeact-coated gold nanoparticles, Lifeact•AuNP 
 
 
 
A solution of Lifeact-FAM (5 mM, in 0.1 M sodium phosphate buffer with 37 % DMSO) was 
titrated into an aqueous suspension of citrate-stabilised AuNP (9.4 nM, in water) (Figure 6.2 
A). The red shift in the SPR band confirms the binding of Lifeact to AuNP. The titration was 
continued until a maximum shift of 4.5 nm in the AuNP SPR band was observed. This 
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maximum shift is indicative of fully coating of AuNP with Lifeact. The interaction of Lifeact 
with AuNP is expected to take place via the cysteine residue at the N-terminus of the peptide. 
The Lifeact-coated AuNP, Lifeact•AuNP, were purified by size-exclusion chromatography to 
remove any excess, unbound Lifeact. Following chromatography, the λmax of the SPR band 
did not shift confirming the unchanged nature of the nanoparticle coating. A solution of 
Lifeact•AuNP exhibited the characteristic fluorescence emission spectrum for FAM upon 
excitation at 480 nm (Figure 6.2 B). The overlap of AuNP absorption and FAM emission does 
not appear to result in quenching of the FAM emission. 
 
 
6.2.2 Labelling of the actin cytoskeleton with Lifeact•AuNP 
To assess the ability of Lifeact•AuNP to label the platelet actin cytoskeleton, washed human 
platelets were allowed to spread on fibrinogen for 45 minutes prior to fixation and 
permeablisation, then labelled with Lifeact•AuNP. The fixed cells were then imaged using 
confocal microscopy (Figure 6.3). Similar labelling pattern was observed for platelets labelled 
with Lifeact or Lifeact•AuNP, indicting labelling of the platelet actin cytoskeleton by 
Lifeact•AuNP. However, very little reflection corresponding to scattering of light by gold was 
observed in confocal reflection images. This is most likely due to dispersion of nanoparticles 
throughout the cell. In Chapter 5 the nanoparticles were gathered together in membranous 
locations which resulted in a higher density of light-scattering nanoparticles at the cell 
surface, in particular, in the centre of the platelet. 
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6.2.3 Conjugation of pHLIP to Lifeact•AuNP via a disulphide bond 
To introduce disulphide bonds between pHLIP and Lifeact•AuNP, use of a disulphide linker, 
N-succinimidyl 3-(2-pyridyldithio) propionate, SPDP, is investigated. SPDP has been 
successfully used to introduce disulphide bonds on to AuNP to facilitate intracellular release 
of siRNA from AuNP carrier (Lee et al., 2009). It has also been used to provide a disulphide 
bond between pHLIP and phalloidin and amanitin (An et al., 2010, Wijesinghe et al., 2011, 
Moshnikova et al., 2013). SPDP, once conjugated to the N-terminus NH2 group of Lifeact on 
Lifeact•AuNP will provide a disulphide bond on the nanoparticles (Figure 6.4). Following 
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SPDP conjugation, pHLIP with it C-terminus thiopyridyl group removed, can be conjugated 
to Lifeact•AuNP via a disulphide bond. 
 
 
 
Lifeact•AuNP and buffer compatibility 
A variety of buffers are required during the conjugation reactions. To ensure that the buffers 
are suitable for use with Lifeact•AuNP and do not cause nanoparticle aggregation, UV-Vis 
spectroscopy studies were performed. Lifeact•AuNP was centrifuged to remove water and re-
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dispersed in PBS, sodium borate buffer or PBS with EDTA, PBS-EDTA. UV-Vis 
spectroscopy of the SPR band was used to monitor the effect of the buffers on the 
nanoparticles (Figure 6.5). 
 
 
 
There was no shift in the SPR band following buffer replacement for any of the buffers tested. 
However, there was a reduction in the Lifeact•AuNP concentration when re-dispersed in PBS-
EDTA which corresponds with the nanoparticles sticking to the tubes following re-dispersal. 
This sticking of nanoparticles was not observed for either of the other buffer samples. 
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Therefore, while PBS-EDTA is not suitable for use with Lifeact•AuNP, PBS and sodium 
borate buffer appear not to affect the nanoparticles so are suitable for use with nanoparticles. 
 
Conjugation of SPDP to Lifeact•AuNP 
As described by Lee et al, SPDP (400 μL, 3 mM in PBS with 10 % DMSO) was added to 
Lifeact•AuNP (400 μL, 30 nM in PBS) and stirred vigorously for 45 minutes at room 
temperature (Lee et al., 2009). Nanoparticles were found to adhere to the glass vial following 
addition of SPDP to the nanoparticles. There was a red shift in the λmax for the nanoparticle 
SPR band indicating a shift in the surface composition of AuNP (Figure 6.6 A). This shift was 
accompanied by a broadening of the SPR band. Also a reduction in the absorbance arises as a 
result of loss of nanoparticles through adhesion to vial. There was no loss of nanoparticles and 
no shift in λmax for, or broadening of, the SPR band of Lifeact•AuNP treated with solvent 
control (400 μL, PBS with 10 % DMSO), indicating that SPDP was responsible for changes 
to the AuNP properties. 
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SPDP-Lifeact•AuNP was centrifuged to remove unconjugated SPDP and the nanoparticles re-
dispersed in sodium borate buffer. During washing by centrifugation nanoparticles were 
observed adhering to vial, this was not the case for solvent control Lifeact•AuNP. Following 
centrifugation, the λmax of the SPR bands did not shift confirming the unchanged nature of the 
nanoparticle coating (Figure 6.6 B). 
 
pHLIP-Lifeact coated gold nanoparticles, pHLIP-Lifeact•AuNP 
The C-terminus thiopyridyl group of pHLIP was removed via treatment with TCEP, a 
disulphide reducing agent, exposing the sulphydryl group, pHLIP-SH. TCEP was selected 
over other disulphide reducing agents such as, dithiothreitol, DTT, and 2-mercaptoethanol, 2-
ME, because it does not contain thiol-groups and therefore does not need to be removed prior 
to addition to SPDP-Lifeact•AuNP. This reaction was carried out several days before use with 
AuNP to enable oxidation of TCEP in the phosphate buffer. Additionally pHLIP was 
dissolved in DMF instead of DMSO since DMSO promotes disulphide formation. 
 
pHLIP-SH (16 μM, in sodium phosphate buffer with 37 % DMF) was added to SPDP-
Lifeact•AuNP (15 nM, in sodium borate buffer) and incubated for 18 hours at room 
temperature. Nanoparticles were found to aggregate during incubation as evidenced by 
suspension changing colour from a semi-opaque red wine colour to a translucent blue/grey 
colour. This was also found to be the case when PBS was used as the nanoparticle buffer 
instead of sodium borate buffer. This suggests that use of SPDP to provide a disulphide bond 
between pHLIP and Lifeact•AuNP or the method is not suitable. 
 
Chapter 6 – Delivery of Lifeact coated gold nanoparticles using pHLIP 
Page | 171 
Lee et al re-disperse their nanoparticles in buffers containing the surfactant, Tween20 (Lee et 
al., 2009). Its presence in the nanoparticle suspension will prevent nanoparticle aggregation 
since, as an emulsifier, Tween20 saturates binding sites on surfaces. However, Tween20 also 
lyses cell membranes. Consequently, its presence in the nanoparticle samples negates the need 
for delivery via pHLIP since nanoparticles would enter the platelets through the disrupted 
membrane. Additionally, the platelets would no longer be suitable for live cell imaging 
studies. Therefore, it may not be possible to introduce a disulphide bond on AuNPs without 
the use of a surfactant. 
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6.4 CONCLUSIONS 
This work has demonstrated that 13 nm gold nanoparticles can be functionalised with 
fluorescently labelled Lifeact. This functionalisation enables labelling of the actin 
cytoskeleton in permeablised platelets with both a fluorescent label and a gold nanoparticle. 
These peptide coated nanoparticles are stable in a variety of cell buffers, so could be suitable 
for use with live cells. However, it also demonstrates that confocal reflection microscopy may 
not be a suitable technique for light microscopy imaging of gold nanoparticles which are 
dispersed throughout the cell. Instead a dark field microscopy technique may be more suitable 
(Wax and Sokolov, 2009). 
 
Attempts at conjugation of pHLIP to AuNP via a disulphide bond between pHLIP and AuNP-
bound Lifeact were unsuccessful. The presence of sulphur groups external to the AuNP 
surface, resulted in binding of nanoparticles to glass surfaces, as evidenced by adhesion of 
SPDP-Lifeact•AuNP to vials. Furthermore, when pHLIP-SH was added, the nanoparticle 
suspension completely aggregated. These results indicate that creation of a disulphide bond on 
gold nanoparticles may not be possible without the use of a surfactant to prevent aggregation 
of nanoparticles. Therefore, another method of releasing nanoparticles from pHLIP may be 
more suitable than disulphide bond cleavage and should be considered in future. 
 
In conclusion, while Lifeact-coated gold nanoparticles may provide a multi-modal imaging 
label for the actin cytoskeleton, its use in live cells is hampered by the current inability to 
deliver and release it into the cytoplasm of cell. Conjugation to pHLIP would enable 
cytoplasmic delivery of Lifeact•AuNP but this work suggests its intracellular release is not 
possible via a disulphide bond, as previously observed.  
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CHAPTER 7 
GENERAL DISCUSSION 
 
7.1 Summary of results 
The work presented in this thesis can be divided into two sections: the first section 
investigates the role of actin nodules in mouse platelets while the second section focuses on 
delivery of imaging labels into human platelets to enable investigation of actin nodules in 
human platelets. 
 
I have demonstrated the ubiquitous presence of actin nodules in early spreading stages of 
mouse platelets. I have presented evidence for their dynamic nature, i.e. their rapid turnover, 
as a result of actin polymerisation and depolymerisation. Additionally, I have demonstrated 
that actin nodule formation requires Arp2/3 complex and calcium ions, while ROCK appears 
to play a role in the stability of formed nodules. The nodules are stationary, localised to the 
basal cell membrane and co-localise with integrin clusters. 
 
I have demonstrated the potential of pHLIP as a delivery vector for use in ex vivo platelets by 
the successful delivery of both Lifeact and gold nanoparticles into live cells. Furthermore, I 
have presented evidence that once translocated across the cell membrane, the disulphide bond 
between pHLIP and Lifeact is cleaved enabling labelling of the platelet actin cytoskeleton. 
Incubation of platelets with pHLIP, pHLIP-Lifeact or pHLIP-coated AuNPs does not appear 
to affect the ability of platelets to spread on a fibrinogen coated surface. I have shown the 
suitability of the Lifeact peptide as an externally introduced actin label for live cell imaging 
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studies in platelets. Additionally, I have presented evidence of the suitability and usefulness 
of gold nanoparticles as a label for multimodal imaging applications. 
 
 
7.2 The role of actin nodules in platelets 
The presence of actin nodules in all platelets during early platelet spreading stages suggest 
that they play an important role in platelet spreading. Their transient nature, high turnover and 
localisation to the cell periphery or base of filopodia suggest this role may include mediating 
the formation of other actin structures such as filopodia and lamellipodia. Furthermore, the 
location of these nodules at the basal cell membrane, co-localisation with integrin clusters and 
stationary position allude to a possible role in adhesion of platelets to the exposed ECM. This 
is supported by their close proximity to the ECM in platelet adhesion under shear stress 
(Kasirer-Friede et al., 2010). Since focal adhesions are present in platelets when stress fibres 
are, these transient actin structures may be similar to actin-based adhesion precursors or 
nascent adhesions which form prior to stress fibre formation (Cerecedo et al., 2006, Choi et 
al., 2008). 
 
 
7.3 pHLIP as a delivery vector in human platelets 
pHLIP synthesised with a thiopyridyl group on the C-terminal cysteine residue enables easy 
conjugation of a cargo molecule to pHLIP’s C-terminus. In previous work by Engelman et al, 
extra synthetic steps were required to introduce a linker group to facilitate conjugation via a 
disulphide bond (Reshetnyak et al., 2006, An et al., 2010). The presence of the thiopyridyl 
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group served two purposes: Firstly, its presence protects the cysteine residue by preventing 
disulphide bond formation between cysteine residues on pHLIP and consequently preventing 
dimerisation of pHLIP in solution. Secondly, the thiopyridyl group provides an efficient 
leaving group, thus enabling disulphide exchange between the thiopyridyl group and an 
unprotected –SH group of a cargo molecule. The later function was demonstrated by the 
conjugation of pHLIP to the fluorescently labelled Lifeact via a disulphide bond in Chapter 4 
and to 13 nm gold nanoparticles via a gold-sulphur bond in Chapter 5. 
 
Conjugation to pHLIP enabled successful cytoplasmic delivery of both Lifeact and AuNPs in 
live human platelets. Immunogold labels and the actin label, phalloidin, have traditionally 
been introduced via permeablisation of fixed cells. Similarly labelling of other actin 
regulatory proteins in immunohisochemistry studies is achieved by fixation and 
permeablisation. Therefore, this represents a major step forward in the ability to undertake 
live-cell fluorescence imaging studies in human platelets. Conjugation of pHLIP to 
fluorescently labelled antibodies to actin regulatory proteins, etcetera, via a disulphide bond 
could enable live-cell imaging of those proteins in human platelets thereby providing detailed 
understanding of their dynamics and interactions during platelet spreading. 
 
There was a high degree of localisation of pHLIP and pHLIP-cargo to the central region of 
the platelets. In this region, the disulphide bond between pHLIP and Lifeact appeared to not 
be cleaved. A similar pattern of cellular localisation has been observed for re-localisation of 
platelet receptors occurs during platelet spreading resulting in increased concentrations in the 
granulomere region (Lewis et al., 1990, Kieffer et al., 1992). It may be that there is an excess 
of pHLIP-cargo on the platelet membrane which has not translocated the platelet membrane 
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and this excess is re-located to the platelet centre during spreading. Alternatively, the presence 
of many disulphide isomerases on the platelet surface could result in cleavage of the bond 
between pHLIP and its cargo (Cho et al., 2008, Essex et al., 1995, Holbrook et al., 2010, 
Jordan and Gibbins, 2006, Manickam et al., 2008, Robinson et al., 2006). This could result in 
endocytic uptake of the membrane bound pHLIP and cargo molecules and their localisation to 
the platelet granulomere. This may account for the few nanoparticles observed in vesicles. 
 
Incubation of platelets with <10 μM pHLIP does not appear to affect platelets in suspension. 
However, following incubation in suspension, washing of platelets via centrifugation to 
remove pHLIP or excess cargo, results in loss of platelets. This suggests that the presence of 
pHLIP on the platelet membrane may cause slight activation of the platelets. TEM images of 
platelets treated with pHLIP-coated nanoparticles (Chapter 5) showed that the discoid shape 
of the platelets is not maintained suggesting activation of the platelets, although it is not clear 
whether this is due to pHLIP or the nanoparticles. Nevertheless, platelets appear to spread 
normally following pHLIP treatment. 
 
Therefore, pHLIP has potential as an intracellular delivery agent for ex vivo platelets. 
However, further investigation is required to fully explore the effect of pHLIP on platelets and 
to reduce the high localisation to the platelet granulomere which currently impedes live cell 
imaging studies. 
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7.4 Labelling and imaging actin in human platelets 
The actin cytoskeleton plays a fundamental role in platelet spreading and aggregation and in 
cellular processes in other cells, including cell division and migration (Cande et al., 1977, 
Wehland et al., 1977). Additionally, impairments in cytoskeletal function are implicated in 
diseases including Alzheimer’s and cancer (Bamburg and Bloom, 2009, Suresh, 2007). 
Staining and imaging of actin has been vital in studying the actin cytoskeleton. In platelets, 
actin labelling is achieved using fluorescently labelled phalloidin which is introduced via 
permeablisation of the membrane of fixed platelets. Introduction of Lifeact peptide into fixed 
human platelets via permeablisation, produced similar labelling to phalloidin (Chapter 4). 
Therefore Lifeact peptide could be used as an alternative to phalloidin in fixed cell studies in 
platelets and other cells. Its small size (17 aa) means it could be easily and cheaply 
synthesised whereas phalloidin is generally extracted from Amanita phalloides, a procedure 
which is expensive and elaborate, since it has proved difficult to synthesize (Wieland et al., 
1983). 
 
For live cell studies Lifeact has been expressed as a GFP-fusion protein in cultured cells and 
mouse models (Era et al., 2009, Riedl et al., 2008, Godin et al., 2011, Riedl et al., 2010, 
Schachtner et al., 2012). Platelets from a Lifeact-GFP mouse model have enabled imaging of 
platelet actin dynamics during spreading. Although this has previously been achieved using 
platelets from GFP-actin mice, there is evidence that Lifeact-GFP does not affect actin 
dynamics to the same degree as actin-GFP(Deibler et al., 2011). 
 
However, platelets are non-transfectable, as are primary neutrophils and other cells such as, 
oocytes, are difficult to transfect. While introduction of Lifeact peptide to these cells may be 
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possible via microinjection or scrape loading, these methods are inefficient, labelling only a 
few cells, or causing damage to the cells (McNeil et al., 1984, Li et al., 2008). Conjugation of 
the Lifeact peptide to pHLIP presents a method which enables uptake into non transfectable 
cells. Lifeact delivered thusly was able to label the human platelet actin cytoskeleton in live 
cells. However, in platelets, this method requires further investigation since currently a high 
degree of labelling of the central region of the platelet hampers the ability to image the cells 
spreading. pHLIP has been successfully used to deliver C-terminally conjugated cargo 
molecules to a variety of cells including HeLa and mouse prostate (TRAMPC1) and breast 
(JC) cancer cell lines (Reshetnyak et al., 2006). Therefore, pHLIP may provide a suitable 
method to enable live cell imaging of actin cytoskeleton dynamics in many cell types through 
Lifeact labelling. 
 
 
7.5 Gold nanoparticles as imaging labels in human platelets 
Gold nanoparticles have been traditionally used in immunogold labelling for electron 
microscopy studies in platelets. However, gold nanoparticles are also suitable for light 
microscopy studies due to their ability to scatter light (Kah et al., 2008, Wax and Sokolov, 
2009). Additionally, their functionalisation with fluorescent labels provides another 
application in fluorescence microscopy. Functionalisation of 13 nm gold nanoparticles with a 
luminescent europium complex (Chapter 5) or fluorescently labelled Lifeact peptide 
(Chapter 6) enables visualisation of the nanoparticles in human platelets via fluorescence or 
luminescence microscopy, confocal reflection microscopy and transmission electron 
microscopy, thus demonstrating their potential as imaging labels for multimodal imaging. 
Furthermore, having demonstrated pHLIP-mediated cytosolic delivery of europium coated 
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nanoparticles into platelets, replacement of the europium ion with another lanthanide such as 
gadolinium, transforms these nanoparticle labels from luminescent ones to magnetic 
resonance imaging, MRI, labels. 
 
With the rise in popularity of correlative light and electron microscopy techniques to provide 
dynamic and temporal resolution and high spatial resolution, respectively, of cellular process, 
gold nanoparticles provide an ideal label for such applications (Sartori et al., 2007, Cortese et 
al., 2009, Vicidomini et al., 2009). In platelets, this technique has been used to study 
fibrinogen receptor movement (Olorundare et al., 1992). Intracellular delivery of 
nanoparticles by pHLIP could provide an ideal system of labelling for correlative light and 
electron microscopy in human platelets. 
 
 
7.6 Final thoughts 
In this thesis, I have further characterised the actin nodule and their ubiquitous in the early 
platelet spreading stages suggest their importance in platelet shape change. However, their 
precise role is not known and further research is required to gain a greater understanding of 
the role of actin nodules in both human and mouse platelet spreading. Additionally, I have 
demonstrated the potential of pHLIP as a delivery vector for human platelets. Although, 
successful intracellular, cytoplasmic delivery of Lifeact and luminescent nanoparticles was 
achieved, this method still needs further research, particularly to address the excess 
accumulation of pHLIP and its cargo in the central region of platelets. 
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